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SUMMARY
Malaria, a devastating disease that primarily affects individuals in developing na-
tions in the tropics, is caused by parasites from the genus Plasmodium. Much time
and money has been invested to better understand the underlying biology of both
the parasite and the host response to infection with the ultimate goal of improving
malaria treatment and prevention. In this thesis, I explored the host response to
both anti-malarial drugs as well as to various infection peak types. I found that the
host transcriptome and metabolome are greatly altered in response to pyrimethamine,
an important anti-malarial drug, and I characterized the specific gene sets that are
dysregulated. The nature and persistence of gene expression dysregulation after
pyrimethamine treatment raises important questions concerning the prolonged use
of this drug.
While many genes are altered in response to the anti-malarial drug, pyrimethamine,
the host transcriptome is extensively altered during a primary parasitemia peak in
a P. cynomolgi infection of Macaca mulatta. However, in response to relapsing par-
asitemia peaks, the host transcriptome behaves in a qualitatively different manner.
Specifically, there is extreme response to the primary infection with almost no re-
sponse to relapsing parasitemia peaks. Some of the dysregulated pathways in the
primary malaria infection peak overlapped with previously-identified gene set and
suggest a relationship with auto-immune etiology.
After computationally defining parasite life-stage-specific gene sets, I also profiled
the parasite transcriptional response to multiple infection peaks. Much like in the
xxv
host transcriptional response, parasite gene expression was qualitatively very differ-
ent between primary and relapsing parasitemias. Specifically, there is a shift away
from sexual stage parasites in the relapsing parasite population. I also describe an
artemether-induced difference in the parasite transcriptome, which will require further
experimental validation.
Lastly, I examine the parasite molecular machinery that is associated with anti-
genic variation. I found that, as anticipated, SICAvar transcription is down-regulated
genome-wide in parasites passaged in splenectomized primates. Further, I identified
many exported proteins that are also down-regulated and which may play a role in
the control of SICAvar expression in its broadest sense. Further investigation will
help refine the roles of each of these co-regulated genes in the expression of variable




1.1 Malaria - a persistent killer
Approximately a quarter of a billion people are stricken with malaria infections each
year, and nearly one million deaths result, mostly in children under 5 years of age.[56]
Malaria is an infectious disease caused by unicellular eukaryotic parasites of the genus
Plasmodium. Once bitten by an infectious mosquito, patients will often not experience
symptoms for one to four weeks.[42] When the patent blood-stage parasites emerge,
patients will experience flu-like symptoms which include headache, fever, chills, vom-
iting, and muscle pain.[98, 42] Clinically, malaria infection can lead to anemia, and
in severe cases, patients may experience coma or death.[69, 68, 92, 98, 42]
Malaria infections are geographically concentrated in the tropical regions of the
world: Africa, Latin America, and Southeast Asia and Oceana (Figure 1A,B).[12, 53,
18, 52, 19] In these regions, it is mostly developing countries that bear the majority
of malaria cases. This pernicious disease impacts not only human health but also
had broader economic impact.[40, 129, 31] Historically, the range of malaria extended
well into Southern Europe and the southern United States.[93, 125] Recently, however,
vector control programs have limited mosquito populations and thereby eliminated
stable transmission of the disease in most developed Western countries.[75, 32] In
spite of the fact that nearly half of the world’s population is at risk of contracting
malaria, there is still no approved and effective vaccine for this disease.[2]
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Figure 1: Malaria endemicity and genetic resistance. Global distribution of
(A) P. falciparum and (B) P. vivax in human populations. (C) The prevalence of
G6PD deficiency. Panels A-C from [53, 52, 65], respectively.
1.2 Human impact of malaria
Malaria infection has exacted a large fitness cost on the human population.[147, 79,
162, 60, 61, 27] As mentioned above, the majority of malaria-related deaths occur
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in children. Furthermore, the anemia caused by high parasite loads may also play a
role in reducing host fitness. Based on population genetics, it has been inferred that
the numerous polymorphisms that confer resistance to malaria have experienced high
levels of positive selection in the past 10,000.[147, 124, 60, 162]
Perhaps the most widely known and referenced human polymorphism of malaria
is the sickle-cell mutation (HbS) in the gene that codes for hemoglobin B (HbB).
This point-mutation (glutamic acid to valine, E6V) at the sixth amino acid residue
of hemoglobin leads to an aggregation of hemoglobin inside the red blood cell when
the hemoglobin is not binding oxygen. In spite of the negative consequences of being
homozygous for this mutation, the sickle-cell allele is at moderate allele frequency
(≈15-20%) in many malaria-endemic regions.[119] Based on haplotype analysis, it is
hypothesized that the sickle-cell trait arose independently in at least four populations,
a observation that provides evidence for the high selective pressure that malaria has
exerted on human genome evolution in the recent past.[79, 1, 61] Furthermore, there
are two other novel mutations in the hemoglobin B gene, HbC and HbE, that confer
protection against severe malaria.[4]
There are countless other mutations that have been selected for their ability to
protect against malaria mortality and morbidity.[147, 79, 162, 60, 61, 27] For exam-
ple, there are α- and β-thalassemias, glucose-6-phosphate dehyrogenase (G6PD) defi-
ciency, and the Duffy-negative phenotype1. Most of these loci show high population-
level signatures of positive selection in the recent past (i.e. within the last 5,000 to
10,000 years).[79, 61] These traits all offer the host resistance to the parasite at the
level of the red blood cell.
1On a more technical note, it should be said that while there is some evidence for protection
against malaria for heterozygotes of Duffy negative genotype (i.e. the FY*O allele), it is generally
considered recessive. That is, only those individuals who are homozygous for the Duffy negative
allele will receive the protection against malaria. This offers evidence that P. vivax was not the
driving selective force for the near fixation of the Duffy-negative allele in African populations. Other
members of Plasmodium lineage may have been the cause of selection for the FY*O allele.
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In addition to alterations in the red blood cell phenotype, it is also likely that
malaria exerted selection pressures that have shifted the host immune response. For
example, there is an human leukocyte antigen (HLA) locus that is highly protective
against severe malaria, HLA-b53.[62] While many loci that provide protection against
severe malaria have been identified, there are likely many others that have yet to be
discovered.
And there are at least intimations that the selective pressures imposed by malaria
infection have affected hosts in such a way as to make them more susceptible to
other immunological disorders.[157] This large number of malaria-resistance loci in
the human genome clearly demonstrates the importance of malaria not just in the
number of cases and fatalities caused each year, but also in the indelible mark that
it has left on the evolution of our species.
1.3 Parasite life cycle
Historically, four (and recently a fifth, P. knowlesi) species have been known to cause
malaria in humans.[113, 138, 117, 34, 41, 88] Of these four, Plasmodium falciparum
is the most well-studied.[47, 23, 37] It causes both the greatest number of malaria
infections each year, as well as the most deaths. P. vivax is the next most highly
abundant malaria parasite in terms of human cases. It is the most common malaria
parasite outside of Africa and has high prevalence in Latin America and Asia. It is
nearly absent from Africa due to the near fixation of the Duffy-negative allele.[160, 86]
The other two parasites are P. malariae and P. ovale, and these two species account
for relative few malaria infections (less than 5%). These protozoa are transmitted from
human to human via the invertebrate vector, mosquitoes of the genus Anopheles. The
entire human component of the Plasmodium life cycle is haploid. The only diploid
stages occur in the mosquito.
After an infective mosquito bites a human (or other host), the injected sporozoites
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then migrate to the liver where they invade host hepatocytes (Figure 2). In some
Plasmodium species like P. vivax and P. cynomolgi, some of the parasites enter into
a dormant liver stage, the hypnozoite stage, which can be reactivated to produce
a relapse infection. The remaining parasites begin active growth and division and
subsequently produce multiple exo-erythrocytic schizonts that rupture the hepatocyte
and form merozoites that will then enter the bloodstream and invade a host red blood
cell. Within the red blood cell, the parasite will cycle through the intra-erythrocytic
development cycle (IDC), passing through ring, trophozoite, and schizont stages. The
parasite will then burst the infected RBC, producing between eight and 32 merozoites
that can then infect other red blood cells. Some of the parasites in the blood will leave
the asexual development of the IDC and develop into gametocytes, the sexual form
of the parasite. Production of gametocytes is an essential part of the transmission
process. It is the gametocytes that are taken up by the mosquito and subsequently
develop into the gametes which later form the zygote.
1.4 Parasite gene expression
Throughout its various stages of development, the malaria parasite experiences dra-
matic alterations and cyclic expression of numerous genes across its genome.[23, 24]
Perhaps the most well-studied section of the transcriptome of Plasmodium is the IDC,
which is readily abundant in the host bloodstream.[23, 24, 37, 44, 97, 110] Bozdech
and colleagues performed a competitive hybridization gene expression study using
microarrays, and elegantly demonstrated the cyclic and tightly regulated waves of ex-
pression across the 48-hour IDC of P. falciparum.[23] More recently, Bozdech and col-
leagues showed that the same cyclic regulation in P. vivax.[24] In yet another seminal
contribution by Bozdech and colleagues, researchers showed that protein abundance
of most genes across the IDC was highly correlated with transcript abundance, albeit
with an average time delay of 11 hours.[44]
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Figure 2: Life-cycle of Plasmodium. (1) An infected Anophiline mosquito takes
a blood-meal from a host and transfers infective sporozoites. (2) The sporozoites
enter the bloodstream and eventually enter a hepatocyte. (3a) For some species of
Plasmodium, the parasite can then enter a dormant (hypnozoite) stage within the
hepatocyte. (3b) Other parasites will go through develoment in the exo-erythrocytic
development in the liver cell, eventually forming schizonts. (4) The schizonts rupture
spilling merozoites into the blood stream. (5) Merozoites enter red blood cells and
begin the intra-erythrocytic development cycle (IDC) and undergo many rounds of
asexual reproduction. (6) Some of the parasites then switch to a sexual development
stage forming gametocytes. (7) These gametocytes are then taken up by a biting
mosquito where the parasite undergoes further development, completing its life cycle.
Figure and legend adapted from Galinski, Meyer and Barnwell (2013).
As described above, some parasites exit the asexual development of the IDC
and enter into sexual development as gametocytes. The transcriptional patterns
of this stage have also been studied, and many gametocyte-specific genes have been
identified.[164, 136, 72] In addition to the above-mentioned studied which were all
performed in vitro in laboratory culture, both in vivo and ex vivo studies of parasite
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transcription in various mammalian hosts have been performed.[37, 87, 36, 83]
While there have been many studies which have examined parasite gene expres-
sion, there have not been any published reports (to my knowledge) that investigate
alterations in parasite gene expression across multiple infection peaks within the same
host. The elucidation of the nature of parasite expression changes over various infec-
tion peaks may shed light on the mechanisms that dictate the severity of disease in
the host.
1.5 Diversity of life-history strategies: antigenic variation
and hypnozoites
In spite of many shared features of the life-cycle and expression profile between the
numerous species of Plasmodium, different species of malaria parasites employ unique
mechanisms for avoiding the host immune system and increasing their reproductive
success. Two of these strategies are directly interrogated in this thesis and will be
discussed in detail in their respective chapters. I briefly introduce antigenic variation
and hypnozoites here.
1.5.1 Antigenic variation
Antigenic variation is the process by which some species of malaria parasite (e.g. P.
falciparum, P. coatneyi, and P. knowlesi) evade clearance by the host immune system
by altering the composition of the cell membrane of the infected RBC. In general,
these parasites export one or a few antigenic proteins to the host cell membrane. In re-
sponse, perhaps, to recognition by the host immune system, the parasite switches the
exported antigenic protein to another of the many antigens in the repertoire in their
genome.[13, 14, 64, 63] The exact parasite molecular machinery used to accomplish
this protein export has not been fully elucidated.[126, 127, 148, 165] Interestingly, it
appears that the presence of the spleen or splenic factors are necessary for the ex-
pression of the variable antigens by the parasite on the iRBC cell membrane.[13, 81]
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The mechanism(s) by which the parasite senses the presence of splenic factors is also
unknown.
1.5.2 Hypnozoites
A second important parasite mechanism for immune evasion is the dormant liver
stage, the hypnozoite, which is employed by a number of malaria parasite species
(e.g. P. vivax, P. cynomolgi, and P. ovale).[66, 45, 15] As described above, after
the mosquito injects the sporozoites into the blood stream of its host, the parasite
migrates to the liver. Some of the sporozoites will immediately begin development and
initiate schizogeny in the hepatocytes. Other sporozoites will enter a dormant stage
called a hypnozoite only to re-emerge weeks, months, or even years later. This delayed
release of blood stages likely increases the complexity of infection (COI): the number
of unique parasite strains in an individual at a given time. A higher COI can result in
a much higher level of out-breeding and may facilitate genetic recombination between
distinct strains of the same parasite species.[28, 30, 35] Increased recombination makes
it easier for P. vivax and other hypnozoite-forming species to improve reproductive
fitness in the face of external pressures (e.g. anti-malarial drugs). This difference
in life-history between P. falciparum and P. vivax may explain why the latter has a
higher genetic diversity and smaller haplotype blocks.[28, 30, 35, 109]
Apart from being a unique component of P. vivax biology, hypnozoites present
an important hurdle in the control and eradication of malaria. Even after curative
doses of co-artemether therapy (Coartem), for instance, the dormant liver stages can
still reactivate.[17] The only FDA-approved anti-malarial drug currently shown to
have anti-hypnozoite activity is primaquine.[17] Primaquine, unfortunately, has only
limited use in many P. vivax -endemic areas because it can cause hemolytic anemia in
individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, a mutation
common in many human populations at risk for malaria.[5, 144]
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1.6 Anti-malaria treatments
In addition to the two above-mentioned antimalarial drugs (primaquine and artemether),
there are many other mechanisms for controlling malaria and treating those who are
infected.
The vaccine which has made the most progress toward regulatory approval is RTS-
S, which targets the circumsporozoite protein.[2, 123] Another recent study found
that using sporozoites dissected from infected mosquitoes salivary glands can yield at
least some short-term protection against malaria infection.[130] In spite of the many
years of malaria vaccine development, an effective vaccine is still not available. Many
difficulties have impeded the development of a malaria vaccine. One such impediment
is that a vaccine requires that the host mount an effective immune response, and it
continues to be difficult to achieve a strong immune response in most individuals who
live in malaria-endemic regions due to immunodeficiency stemming from mal-nutrition
and other socio-economic factors. In the absence of an effective vaccine, continued
enquiry into the underlying biology of the parasite will assist in the development of
other complementary treatment and prevention options, a fact that underscores the
continued need for basic and applied malaria research.
Currently, anti-malarial drugs are one of the defences against the development
of life-threatening severe malaria. Pyrimethamine, an important anti-malarial drug
which is usually paired with a sulfonamide, inhibits the enzymatic conversion of
folate to its active form.[137, 16] In spite of the importance and broad usage of
this drug in the treatment of malaria, there has been little investigation into its
effects on the host at the molecular level. In light of case reports of side effects of
this drug, it is likely that it dysregulates many important molecular pathways of
the mammalian system.[101, 73, 159] Research into this drug’s off-target effects on
the host will inform proper medical usage, especially since pyrimethamine has been
suggested as a treatment for amyotrophic lateral sclerosis (ALS).[80]
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1.7 Malaria Host-Pathogen Interaction Center (MaHPIC)
For most researchers in the malaria field, the ultimate purpose of malaria research is
the elimination of malaria.[45] Due to the complex nature of this disease, achieving
this goal will require a more nuanced and multi-faceted approach than most other
diseases. This difficulty of eradication arises from many factors including the multiple-
staged life-cycle of Plasmodium, as well as the non-linear effects that come from
intervention in the complex ecosystem of interactions involved in disease transmission
cycle.[108, 56] Human intervention to reduce transmission may only shift the burden
to a different age class, or worse, actually increase mortality and morbidity from the
disease.[108, 56] The complexity of this parasite and the host-parasite interaction
demand more research into this devastating disease.
Towards the end of eradication and with all of these challenges in mind, an inter-
disciplinary team from four institutes across the state of Georgia (Emory University,
Georgia Institute of Technology, University of Georgia, and the Centers for Disease
Control and Prevention) were awarded a contract from the National Institute for
Allergy and Infectious Disease (NIAID) to begin to address the gaps in the malaria
knowledge base. As a team, we have generated and will continue to generate and
analyze data from a range of different molecular and cellular technologies including
transcriptomics, metabolomics, lipidomics, proteomics, as well as host and parasite
cell counts and CBCs and more detailed interrogation of immune cell populations
using flow cytometry to quantify both numbers and activity levels of cells from the
innate an adaptive immune systems (Figure 3). Each of these technologies will be
probing a unique part of the host and/or the parasite response. The analysis and
integration of these data types from a 100-day control experiment, a 100-day infec-
tion experiment, and a complementary ex vivo expression profiling experiment are
presented in this thesis.
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Figure 3: Overview of the cores of MaHPIC.
1.8 Specific aims
In CHAPTER II, I describe the analytical methods and integrative techniques which
are used in subsequent infection experiments. I also explore the effects of the anti-
malarial drug pyrimethamine on the transcriptome of the rhesus macaque (Macaca
mulatta).
In CHAPTER III, I investigate the host transcriptional response to malaria in-
fection, specifically interrogating the difference between primary and relapsing para-
sitemia peaks.
In CHAPTER IV, I implement a novel approach to expression deconvolution to
a previously published P. falciparum dataset to identify genes whose expression is
parasite stage-specific.
In CHAPTER V, I assess the qualitative changes in the parasite transcriptome
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between primary and relapsing infection peaks with the goal of identifying and char-
acterizing the qualitative differences between them.
In CHAPTER VI, I conclude the thesis, summarizing my contribution to the
scientific body of knowledge of host-pathogen interactions in malaria.
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CHAPTER II
A SYSTEMS BIOLOGY APPROACH TO DETERMINE
THE EFFECT OF PYRIMETHAMINE ON THE
NON-HUMAN PRIMATE MACACA MULATTA
2.1 Abstract
The Malaria Host-Pathogen Interaction Center (MaHPIC) was established to bring
a integrative systems biology approach to the underlying molecular and cellular pro-
cesses occurring within both the host and the pathogen during malaria infection.
Herein, I present analysis from a control experiment in which rhesus macaques were
profiled over a 100-day experiment.
This chapter is composed of two primary parts: the description of a method-
ology for the integration of multiple data-types including two omics technologies,
and the examination of the biological impact on the host of pyrimethamine, an
anti-malarial drug. Especially when used in combination with other antifolates,
pyrimethamine, a common anti-malarial drug (AMD), has been shown to cause bone
marrow suppression (BMS). Also known as myelotoxicity, BMS is the decrease in var-
ious blood cell populations (red blood cells, immune cells, and platelets) likely due to
pyrimethamine’s disruption of folate cycling. Currently unanswered questions exist
concerning both the duration of cellular process disruption after pyrimethamine ad-
ministration as well as the rapidity of clearance in subsequent exposures. In this study,
I will examine the effect of pyrimethamine on the transcriptome and metabolome of
the rhesus macaque. I further characterize the molecular pathways that are disrupted
after administration of this drug.
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2.2 Introduction
The Malaria Host-Pathogen Interaction Center (MaHPIC) was established to bring
a integrative systems biology approach to the underlying molecular and cellular pro-
cesses occurring within both the host and the pathogen during malaria infection.
To this end, MaHPIC researchers experimentally will infect rhesus macaques with
different strains and species of Plasmodium, which serves as a well-established pri-
mate model for human malaria. As controls for these studies, macaques were inocu-
lated with a mock sporozoite preparation (which contained no Plasmodium parasites).
These control macaques were then followed over the course of 100 days and given anti-
malarial drugs on the days that the infected animals were expected to need treatment.
This experiment offers both the opportunity to describe the methodologies that I will
employ to integrate the data. The data generated herein will also be leveraged to
shed light on the effect of pyrimethamine, an anti-malarial drug (AMD), on the host
animals in the absence of malaria infection.
In this chapter, I first lay the foundation of the analytical framework which will
be used in subsequent chapters for integrating some of the numerous data-types pro-
duced by MaHPIC cores. These include complete blood count (CBC) measures (taken
daily), metabolomic data (various samples) and transcriptomic data (taken at seven
points). The methods that I will use include variance component analysis, principal
component regression, analysis of variance (ANOVA) for differential abundance anal-
ysis, and subsequent pathway enrichment. The methods chosen reflect methods used
by recent large-scale projects for data integration, but are adapted due to underlying
experimental design differences.[38, 29]
2.2.1 Effects of pyrimethamine
In addition to giving a detailed description of the methodologies that will be used
in future MaHPIC experiments, I also investigate the effect of the anti-malarial drug
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pyrimethamine on the host transcriptional profile at both the level of the individ-
ual transcript as well as the pathway scale. Pyrimethamine, a potent and front-
line malaria treatment when paired with a sulfonamide, inhibits dihydrofolate re-
ductase (DHFR), an enzyme responsible for the conversion of dihydrofolate (DHF)
into tetrahydrofolate (THF).[137, 16] The resulting depletion of THF has impor-
tant consequences for the cell, especially rapidly dividing cells like those of the
parasite.[105] Folate-deficiency-induced reduction in the availability of nucleotide pool
and subsequent cell cycle arrest of the parasite is the putative mechanism of action of
pyrimethamine.[134] In spite of pyrimethamine’s important position as a treatment
of malaria, its side-effects on the host have not been fully elucidated.
The host, in this case the macaque, also possesses DHFR, and pyrimethamine will
presumably inhibit its functioning, as well, leading to a host cell reduction in THF.
THF is a co-enzyme for the production of three of the four deoxyribonucleotides,
which are in high demand during the genome duplication of mitosis. THF is also a
co-factor for the metabolism and methylation of some amino acids, and a reduction in
THF therefore can deplete the amino acid pools of the cell and may also dysregulate
post-translational modification of proteins.[9]
Yet another important consideration for pyrimethamine usage is that approxi-
mately 40% of cellular folate is present in the mitochondria, reflecting its importance
in the functioning of this energy-producing organelle.[132, 85] Based on its underlying
molecular mechanism or action, the administration of pyrimethamine is likely to have
dramatic effects on the transcriptome of the host. To assess the magnitude and du-
ration of effect of pyrimethamine administration, I will test the following hypotheses.
2.2.2 Motivating Hypotheses
With respect to the host response to pyrimethamine, I anticipate vast alterations in
the transcriptional profile after AMD treatment. First, I hypothesize that both the
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blood and the bone marrow expression profiles will be affected in the samples taken
only seven days after AMD treatment. I anticipate alterations in the folate pathway
and anticipate that many such genes will be up-regulated in the “treated” time points
as the cell works to restore folate levels. Since pyrimethamine reduces the levels of
THF and subsequently purines, a building-block for DNA synthesis, cells that need
high levels of nucleotides (i.e. those that are dividing and copying their genome)
will likely undergo apoptosis. At a minimum, cell cycle progression will be affected.
A more pronounced effect is expected to occur in the bone marrow compared to the
whole blood since the bone marrow contains many rapidly-dividing cell types whereas
the blood is relatively post-mitotic.
Secondly, I hypothesize that in the two time points that are >30 days after the
last AMD treatment (“inter,” TP4 and TP6), both blood and marrow expression
profiles will have returned to normal. The alternative hypothesis is that more than
a month after AMD treatment, gene expression programs in marrow and blood are
still dysregulated. A finding of this nature should inform decisions concerning mass
administration of AMDs as a way of eradicating malaria versus targeted treatment
of confirmed-infected individuals.
In this chapter, I begin by describing the analytical methods which will be used in
this and subsequent chapters for integrative analysis. Next, I explore the correlation
structure and variance components of the datasets. Finally, I describe findings regard-
ing the transcriptional dysregulation that occurs and persists after pyrimethamine
administration.
2.3 Methods and materials
2.3.1 Experimental design and measured outcomes
The Malaria Host-Pathogen Interaction Center (MaHPIC) is a multi-disciplinary in-
vestigation that utilizes multiple data types to better understand the systems biology
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of the complex host-parasite dynamics in the course of malaria infection. For this
control experiment, the design is as follows. Five male rhesus macaques (Macaca
mulatta) approximately 2 years of age were profiled over the course of a 100-day
experiment after being injected with purified mosquito salivary glands on day 0 of
this control experiment. Complete blood counts were performed daily by the Malaria
core members. Before injection, the timepoint 1 (TP1) samples were taken. Then,
at days 20, 26, 53, 59, 89, and 96, members of the Malaria core collected blood and
marrow samples for TP2-7, respectively. The transcriptome and metabolome were
interrogated at seven (TP1-7) and five (TP3-7) milestones throughout the course of
the experiment, respectively (Figure 4).
2.3.2 Metabolomics feature quantification
High resolution metabolomics was performed by the Metabolomics core using a liquid
chromatography/mass spectrometry (LC/MS) approach on an Orbitrap Mass Spec-
trometer. Two different columns were used for the LC separation stage: C18 and
anion exchange (AE). Each distinct biological sample was run in triplicate to en-
sure high reliability of the data, with randomization within batches. MS peaks were
called using xMSanalyzer.[154] Standard quality control measures were performed,
such that features with greater than 60% missingness or a coefficient of variation
within replicates greater than 1 were removed from the analysis. Since the frequency
distributions of all samples were comparable, no additional normalization was per-
formed, but an abundance cut-off of 256 peak area units was adopted and all features
below this were excluded. All downstream analyses utilized the individual samples
rather than attempting to average or otherwise reduce the technical replicates to a
single measure per biological sample. Each column generates in excess of 10,000 mass-
to-charge (m/z) and retention time features, the majority of which are either not yet
annotated or have ambiguous annotation to multiple possible organic compounds.
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The m/z features include the majority of known components of central metabolism,
as well as xenobiotics.
2.3.3 Library preparation for RNA-seq
Bone marrow (1ml, BM) was collected by the Malaria core into 1.5 ml tubes with
EDTA, and the mononuclear cells were purified by density gradient centrifugation on
Lymphoprep (Stem Cell Technologies) solution and preserved in RLT buffer (Qiagen)
to stabilize mRNA. Whole (peripheral) blood (3 ml, PB) was collected by the Malaria
core team members in Tempus tubes (Applied Biosystems) that also preserve mRNA;
these samples include erythrocytes, platelets and granulocytes in addition to mononu-
clear lymphocytes. RNA was extracted from the BM samples using Qiagen RNEasy
Mini-Plus kits following the manufacturer-recommended procedures, and from PB
samples using Tempus-Spin RNA isolation kits. The quality of all RNA samples was
confirmed using a Bioanalyzer, with an RNA Integrity Number (RIN) greater than 8
recorded for all samples.
Approximately 1 g of total RNA per sample was converted to double-stranded
cDNA using poly-A beads to enrich for mRNA, using Illumina TruSeq Stranded
mRNA Sample Prep kits to generate strand-specific libraries. As a quality con-
trol, 96 spike-in RNAs of known concentration and GC composition (ERCC Spike-In
Control, Life Technologies) were added to constitute approximately 1% of the total
RNA for each library. Adapters were ligated to facilitate 3-plex sequencing on an
Illumina HiSeq2000 at the Yerkes Genomics Core, aiming for 80 million paired-end
100-nucleotide (nt) reads per library.
2.3.4 Short read mapping
To quantify gene expression, the RNA-Seq reads were mapped to the most recent
available rhesus macaque genome (MacaM assembly, Version 4.0, GenBank accession
number PRJNA214746 ID: 214746, created by Aleksey Zimin at the University of
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Maryland, Rob Norgren at the University of Nebraska Medical Center, and their col-
leagues) using Tophat2.[151, 74] Default options were used with the exception that
the command –library-type fr-secondstrand was used since the reads were generated
using a stranded library preparation method from Illumina. This allowed us to dif-
ferentiate between sense and antisense transcripts. We also provided an annotated
reference transcriptome which was supplied with the M. mulatta genome (Version
4.12) which improves the mapping accuracy across splice junctions. Only reads that
map to a single location in the genome were included, to ensure high-confidence map-
ping. All downstream analyses were performed at the level of annotated gene: this
study does not consider exon-specific or transcript isoform relative abundance.
Several quality control steps were used to verify the reliability of the data: linear
correlation of estimated abundance of ERCC spike-in controls with known concentra-
tion; confirmation of 99.9% strand-specificity of the controls; less than 0.1% control
fusion transcripts; and absence of 3 bias in the controls was confirmed with RSeqC
software. Transcript abundance levels were inferred using HTSeq v0.5.4. HTSeq takes
the short-read mapping file (bam) from tophat2 and the gene annotation file which
contains the locations of all annotated genes. Since some libraries were sequenced
more deeply than others, the libraries were normalized before determining differen-
tial gene expression using the gene level expression files with the default parameters
of DESeq version 1.10.1.
2.3.5 Gene expression quantification
After quality control steps verified the reliability of the data, we quantified the gene
expression levels using htseq v0.5.4.[135] HTSeq takes the short read mapping file
(bam) from tophat2 and the gene annotation file which contains the locations of
all annotated genes. We obtained the most updated macaque gene annotations from
rhesusbase. Since some libraries were sequenced more deeply than others, the libraries
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were made comparable (normalized) before determining differential gene expression
between libraries. Gene expression normalization was performed using the library
size estimation procedure implemented by DESeq version 1.10.1, available in the
bioconductor suite in R.[6, 7, 51, 146] Briefly, the software calculates the ratio between
gene expression for a given gene against the geometric mean of all samples in the study.
It then finds the median value across all genes for each individual and uses it as the
library size factor.
2.3.6 Variance component analysis
After data normalization, the transcriptome and metabolome levels were log-2-transformed
and imported into JMP Genomics (version 6.0). To determine how much of the vari-
ance in each of the datasets is explained by the two measured factors (animal and
time), I performed a principal components (PC)-variance component analysis using
JMP v6.0 (SAS) for the transcriptome, metabolome, and the CBC data. This consists
of the generation of all PC explaining up to 90% of the total variance (12 to 15 for
the transcriptomes and 30 for the metabolomes), regressing each PC on Animal or
Timepoint, and generating a weighted average of the squared correlation coefficient
(percent variance explained) across all of the PC. Since the low abundance features
for metabolomics and transcriptomics both have high coefficients of variation, I set
thresholds of 5 log2 units for transcripts and 17 log2 units for metabolites (Supple-
mentary Figure 1) and removed lower abundance features to determine their effect(s)
on the analysis.
To assess whether the major PC capture similar aspects of the data, the first 10
PC were calculated for the four omics datasets (PB and BM transcriptomes, C18 and
AE metabolomes) using JMP. All 780 pairwise correlations of these PC values were
determined, and a Bonferroni multiple comparison adjustment was used to assess the
significance of each pair of PC. Exploratory partial least square regression analyses
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were also performed with MixOmics in attempt to select variables that co-vary, but
did not reveal significant associations.
2.3.7 Differential gene expression (DGE)
The next step in the analysis was the identification of genes that are differentially
expressed across the experimental conditions. For between-TP differences, an analysis
of variance (ANOVA) was performed on each transcript separately using “animal” as
a random effect with 5 levels and “timepoint” with 7 levels, or “drug” with 3 levels
as the fixed effect. For the drug exposure factor, I define our three experimental
conditions as before drug exposure (Pre-drug; TP1 and TP2), 7 days after the most
recent dose (Post-drug; TP3, TP5, and TP7), and 30 days after most recent dose and
immediately before the next dose (Inter-drug; TP4 and TP6), as shown in Figure
1. A false discovery rate cut-off of 5% was used to define differentially expressed
genes. These were examined using hierarchically clustering of the standardized least
squares means and volcano plots of significance against fold difference between specific
conditions.
2.3.8 Gene set enrichment analysis
Gene set enrichment analysis GSEA is most commonly performed in one of two
ways. In the first method, a statistical threshold is set for a list of genes (usually
a Bonferroni-corrected p = 0.05); any gene with a p-value lower than the threshold is
included and a hyper-geometric test for enrichment with other gene sets is calculated.
In the second method, the entire gene list is used, and genes are ranked using
some ranking metric, which is often the t-statistic since it measures both magnitude
and direction of effect in a two-sample comparison.
The second method has the advantage that its results are not dependent upon
the threshold of choice. That is, if one researcher chooses a threshold of p = 0.05
whereas another chooses p = 0.01, the significance levels for the gene set enrichments
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will likely differ. This can effect downstream interpretation.
One of the drawbacks for the second method is that the statistical significance
value has to be calculated empirically from permutations of the data. This requires
running hundreds or thousands of permutations per gene set to obtain empirical p-
values. However, hundreds of gene sets can be interrogated in a matter of minutes
with a standard desktop computer, and so the time considerations were not limiting
in this case.
To perform this analysis, I chose the ranked gene list method and used the Broad
Institute’s GSEA v2.0.14 to perform enrichment analysis.[142] For the two contrast
of interest (pre-versus-post, and pre-versus-inter), we performed gene set enrichment
using the KEGG pathways and GO terms, separately for each tissue. The t-statistic
was used as the rank metric and was obtained from the JMP output file. Gene sets
with an FDR < 25% were considered as significant in accordance with the recommen-
dations of the GSEA software manual. Default parameters were used and included
the removal of gene sets with more than 500 or less than 15 genes.
To perform GSEA, a priori defined gene sets are needed. Since the rhesus macaque
is much less well-studied than the human genome, and considering that the majority
of genes in the macaque genome have well-conserved syntenic orthologs in the human
genome, I used the pre-existing human gene set annotations for this analysis. These
genes sets were obtained from the Broad Institute’s website.
2.3.9 Blood informative transcript (BIT) axes
In addition to principal component analysis, we employed a second method, blood
informative transcript (BIT) axes analysis, which uses an a priori defined set of 9
blood axes, which are composed of genes that covary across many blood transcrip-
tional profiles.[114] This method has been described elsewhere.[102] Briefly, we took
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the genes that make up each of the axes and calculated the BIT score for each individ-
ual for both the blood and the marrow, separately, using the normalized expression
data. Then, we performed one-way ANOVA to test for significant differences across
both animal and time. Since the between-subject variability was so large, we also
performed the analysis with the animal residuals, that is, the error term in the model
after fitting the effect of animal. We then examined the dynamics of the axes scores
over time as before.
2.4 Results
2.4.1 Subject-specific effects dominate variance components in the tran-
scriptome
After normalization and quality assurance of the datasets from the three data types
across the 100-day experiment (Figure 4), I first explored each dataset independent of
the others. First, I performed variance component analysis of each of the datasets to
attribute the variability of the data to either residual (unexplained) variance or one
of the two factors, animal and time. A previous study described high within-subject
conservation of expression of a subset of genes from whole blood in humans,[161] but
it is unclear how much of the variance in the transcriptome is due to inter-individual
variability. I expect to see a moderate to large proportion of the transcriptomic data
sets explained by subject effects. To my knowledge, no variance component analysis
has been performed for a metabolomic dataset of this size; I, therefore have no a
priori expectation for metabolites.
For the transcriptomes of both tissues, PB and BM, as well as the CBC data,
subject effect accounts for a large component of the variance (more than 30%), which
is much larger than the time effect (Figure 5A). That is, greater than 30% of the ma-
jor variance components are explained by subject-to-subject variation. The within-
subject variance in the metabolomics data is much lower (approximately 10%). The
smaller proportion of variance explained by the factor of animal in the metabolome
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Figure 4: Experimental overview and the structure of the data. CBC mea-
surements were taken daily for the course of the 100 day experiment. RNA for
transcriptome analysis was extracted from blood and marrow at seven time points
(TP1-7). Blood plasma was sampled at the last 5 time points for metabolomic analy-
sis (TP3-7). The major sampling time points were selected based on the estimates of
when sampling would occur in the infection experiments. The light blue time points
(TP1 and TP2; pre) are made before the first administration of pyrimethamine.
The red arrows (TP3, TP5, TP7; post) are samples taken 7 days after the start of
pyrimethamine treatment. The yellow arrows (TP4 and TP6; inter) indicate samples
taken more than 30 days after the last pyrimethamine dose.
compared to the transcriptome and the CBC data suggest that there is some buffer-
ing of metabolic alterations in spite of between-individual differences at the level of
transcript abundance.
A recent study contrasting the variance in the transcript and the proteome across
different primate species showed that in spite of alterations at the transcript level,
protein levels were often much closer across species. If the same buffering capacity
of the cell holds true for within-species differences in transcription, I would expect
less variance at the protein level compared to the transcript level with respect to the
between-animal differences. It would then follow that more similar levels of protein
would lead to more similar metabolite levels between individuals.
For all five datasets, the time effect is close to 10% of the variance. In most of the
datasets, more than half of the variance in the data is unexplained by either animal
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or treatment. This residual variance could be explained by either technical variance
introduced by errors in measurement, unmeasured biological factors, or effects which
we are unable to estimate such as subject-by-treatment interaction terms. Specif-
ically, each macaque may be responding uniquely to the drug treatment based on
its underlying genetic background. Without replication, however, these effects are
statistically impossible to estimate.
As others have noted, the coefficient of variation was dependent upon the mean
of the feature for both the transcriptomic and the metabolomic datasets with lower
feature abundance tending to have higher coefficients of variation (Figure 6).[152, 6]
I suspected that this was due to the fact that low abundance features were poorly
estimated, at least in the transcriptomic data. This effect would result in higher
technical variance in the lowly expressed features, and therefore a reduced proportion
of the variance would be explained by our two factors, animal and time. To test this
hypothesis, I removed all genes with expression lower than an average normalized
level of five, and for metabolites, the cut-off was set at 17; this appeared to be the
close to the elbow-point of the graphs.
After removing lowly expressed genes from consideration and assessing this re-
duced dataset, the amount of residual variance not explained by the two factors, ani-
mal and time, decreases sharply for the transcriptomic datasets; this drop in residual
variance is due primarily to an increase in the variance explained by the factor of an-
imal (Figure 5B). This suggests that the variance of the least expressed genes is more
heavily influenced by technical variance. In contrast, the metabolomic datasets did
not experience such an increase in variance explained after removing low abundance
features. Both subject and time explain a similar amount of the variance before and
after data reduction for the metabolomic datasets (Figure 5B). This finding shows
that the low abundance metabolites compared to high abundance metabolites do not
have increased variability due to measurement error. The fact remains, however, that
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Figure 5: Variance component analysis (VCA) for the three data-types.
The effect of animal (that is, the between-individual variance) is more than 30% of
the variance for the two transcriptomes and the CBC data in the full data sets (A).
Whereas the animal effect is much less prevalent in the metabolomic datasets. In the
reduced datasets (B), the factor of animal explains much more of the variance. Note:
a reduced dataset was not generated for the CBC data since it only had 13 measured
features.
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Figure 6: Coefficient of variance changes as a function of mean feature
value. For both of the data-types, there is a relationship between the coefficient of
variation and the mean value for each feature, stemming from increases in technical
and/or biological variability at the lower end of the measurement spectrum. Each
point represents a feature: either a gene or ion peak. Density contours (for every
5%) are included and show that most of the features are maintained after excluding
lower abundance features. A line is drawn at x=5 and x=17 for the transcriptome
and metabolome, respectively. Features lower than this level were excluded in the
reduced dataset used in calculating the VCA. (A) marrow transcriptome; (B) blood
transcriptome; (C) metabolome with AE column; (D) metabolome with C18 column.
Note: the domain for the transcript average level was trimmed to [0,15] and transcript
CV from [0,1] for figure clarity.
lower abundance metabolites have a greater variance, which perhaps indicates that
higher biological variance (that is not correlated to either of our measured variables)
is likely more tolerated for low abundance metabolites.
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2.4.2 Hierarchical clustering
As the next step in my top-down integrative approach, I performed hierarchical clus-
tering of the transcriptome and metabolome. Hierarchical clustering allows the vi-
sualization of similarity between both subjects and measured variables. To visualize
the relationship between the samples in our study, I hierarchically clustered the 70
transcriptomic samples (2 tissues * 5 macaques * 7 time points). The first and deep-
est division was between tissues: all bone marrow samples clustered together and
all whole blood samples clustered together (not shown). Within the blood, each
macaque clustered with itself (Figure 7A). That is, the seven time points for a given
macaque were more closely related to themselves than to similar time points from
other macaques. This is borne out in the principal variance component analysis in
which 36% of the variance in the blood is explained by the animal while only 6% is
explained by time.
Similar to blood, within the marrow, the within primate samples tended to cluster
together. One notable exception was TP4, approximately one month after the first
AMD treatment. Many of the samples from TP4 cluster together (not shown). Once
again, the difference between blood and marrow is reflected in the principal variance
component analysis: within the marrow, time, as a factor, makes up a much large
proportion of the total within-tissue variance (more than 15%) than it does within
blood (about 6%).
In the blood, there is a tight clustering between the individual macaques. Since
each blood cell type has a characteristic expression profile, which allows it to perform
its specified role(s), I hypothesized that the macaques that clustered together in the
expression profile would also have similar levels of the major cell types. However,
upon clustering the samples on the CBC data, I do not observe such a trend (Figure
7B). Therefore, I conclude that the CBC is capturing information about the system
that is non-redundant with the transcriptome. This result is particularly striking
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Figure 7: Hierarchical clustering omics datasets shows lack of correspon-
dence. (A) Heatmap of the blood transcriptome with each primate uniquely colored.
(B) CBC hierarchical cluster for counts of five cell types: RBCs, platelets, monocytes,
lymphocytes, and granulocytes. (C) Heat map of metabolomic data for the C18 col-
umn.
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when considering that both the transcriptome datasets as well as the CBC dataset
have the variance component of animal explaining more than 30% of the variance.
Within the metabolomic datasets (Figure 7C), the clear separation between in-
dividuals seen in the transcriptome does not occur. Importantly, each of the three
technical replicates for each biological sample cluster together. This finding gives
confidence that the machine read-out is capturing reproducible differences that occur
between the samples. While some clustering between time and animal appear in the
metabolome, it is not as clear as in the transcriptome. This is likely because subject
and time effects explain similar levels of the variance in these datasets, about 10%
each in both columns.
2.4.3 Covariance-based approach for data-type integration: principal com-
ponent regression
One commonly used variable reduction strategy is principal component analysis,
which finds the orthogonal vectors of maximum variance in a dataset. To assess the
amount of information shared between the transcriptomic and metabolomic datasets,
I regressed the first 10 principal components of each dataset against each other (Figure
8). The pattern that emerges is informative in many ways.
Firstly, it shows that the two metabolomic datasets are highly correlated (Figure
8, bottom right box). This observation was expected since the two columns measured
metabolites from the same plasma sample; the difference between the two datasets is
the use of different LC columns which optimized peak resolution across a wider range
of metabolites. PC1 and PC2 for the two sets are significantly correlated; many lower
PCs are also correlated. Unlike the metabolomic datasets, the two transcriptomic
datasets, marrow and blood, do not show as much correlation (Figure 8, top left box).
Upon statistical analysis however, we see that PC1, PC2, PC3, and PC4 in blood are
significantly correlated with PC2, PC4, PC1, and PC5 of bone marrow, respectively
(Bonferroni corrected p < 0.05). Such a result is not unexpected considering that the
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two tissues have different functions yet one (blood) is composed of cell populations
derived from the other (marrow). One difference between the tissues is that the
marrow contains many cell types that are rapidly dividing whereas most of the cells
in the blood are post-mitotic and terminally differentiated. In some cases the sign
of the regression is negative, but this is simply a function of PCA which commonly
reverses signs and order of PC due to sampling variance.
Strikingly, there is no significant correlation between the transcriptome PCs and
the metabolome PCs after multiple testing correction (Figure 8, top right (large)
box). This could be explained by the fact that the transcriptome of these two tis-
sues is contained within the cell whereas the metabolome interrogated the plasma
composition. Furthermore, the plasma is not only influenced by metabolites from
blood cells, but also receives metabolites from all tissues in the body. As a result,
these measurements represent a “whole-body” average, whereas the transcriptomes
are tissue-specific, sampled from cells in specific body compartments. This lack of
correlation between the major components of the metabolome and the transcriptome
demonstrates that these datasets are interrogating different components of the host
system.
2.4.4 Blood informative transcript (BIT) axes of variation
As a complementary data reduction method to principal component analysis, I next
examined the the between-animal differences and trajectory of previously identified
BIT axes of variation.[114] These axes covary with some clinical parameters (e.g.
abundance of specific cell types) and are enriched for gene ontology terms (e.g. viral
response, and B-cell activation). To reduce the number of features of the transcrip-
tome examined as well as to assess the impact of normalization, I calculated the BIT
axes scores for these 9 pre-defined axes for the transcriptome dataset using both the
original data and the expression levels after fitting the effect of animal in a linear
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Figure 8: Heatmap of the correlation of the first 10 principal components
of the transcriptome and the metabolome. In the box on the top left (the
correlation between the two transcriptome datasets), there are some significant corre-
lations between the PCs, although there is not a clear one to one mapping (e.g. PC1
for marrow does not correspond to PC1 for blood). In the correlation between the
metabolomic datasets (bottom right box), the significant correlations lie more clearly
on the diagonal, demonstrating that these datasets are capturing similar information.
Between the two data-types (large box, top right), there are no significant correlations
after Bonferroni adjustment.
model. Using these a priori defined gene sets, I found that the axes vary significantly
across both animal and time point (Figure 9). Axes 2-8 for blood and axes 1-3, 5,7,8,
and 9 for marrow were significantly different across the five macaques which shows
that BIT axes are relatively stable over time within an individual (Figure 9A-C).
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Figure 9: Blood informative transcript (BIT) axes of bone marrow expres-
sion as a function of animal and time. Panels (A-C) show the BIT axes 3, 5,
and 7, respectively, which were highly significantly different across the five macaques.
Panels (D-F) show three significantly differentially regulated axes (2, 7, and 9) which
appear to show coherent cycling as a function of the anti-malarial drug dosage.
After removing the effect of animal from the axes, most of the axes change signif-
icantly across time in both the marrow and the blood with some of them varying in
a manner coherent with the times of treatment with the anti-malarial drug (Figure
9D-F). While it is difficult to assign statistical significance to the coherence of the
cycling of axis scores, qualitatively it appears that many of the axes respond to the
drug in predictable ways. For instance, in the marrow, I find that axes 2, 7, and 9 are
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all behaving in a manner consistent with expectation and thus supporting the value
of this data reduction approach for blood and marrow transcriptomics datasets.
Axis 2 genes (Figure 9D), which are related to hematopoesis, were more highly
expressed at the first two time points but have decreased after the first pyrimethamine
administration, and remained low for the rest of the experiment. Both axis 7 and axis
9, associated with viral response and programmed cell death, respectively, appear to
activate in response to pyrimethamine. The later finding is concordant with the gene
set enrichment analysis results, which will be present later.
2.4.5 Differential abundance of genes, metabolites, and blood cell counts
To perform gene set enrichment, I first must identify genes that are differentially
expressed. There is currently much debate as to the best method for identification
of differentially expressed genes for RNA-seq data.[118, 139] Since most RNA-seq
studies have a paucity of samples, information about the variance of expression must
be borrowed across all genes. In some methods, low variance genes have their variance
inflated to account for the possibility of the low variance being due to chance. This
adjustment has the property of making the analysis more conservative and therefore
less sensitive to differential expression.
In this case, I have many samples, and so herein I use an analysis of vari-
ance (ANOVA) approach to determine which features of the transcriptomic and
metabolomic datasets are altered over the course of the experiment. To utilize the
findings made previously in this study, I explore the impact of including “subject” as
a random effect in our significance analysis. I found that there are many genes and
metabolites that are differentially up- or down-regulated as a function of time (table
1). Importantly, without including the animal effect in the model there are many
fewer features identified as differentially abundant in all of the data-types.
In the examination of the hierarchical clustering of the differentially expressed
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Table 1: Significant features for the effect of time. For each dataset, the
number of significant features identified by the ANOVA test is shown for
either fitting the subject effect or not fitting it.
Data type tissue fitting subject not fitting subject
RNA-seq whole blood 292 0
RNA-seq bone marrow 6483 3678
Metabolome (AE) plasma 3951 1394
Metabolome (C18) plasma 7113 3487
CBC whole blood 13 10
genes for the marrow, TP4 is most different from the other time points (Figure 10A).
I also noticed a similar trend for TP5 in blood (Figure 10B). As a result, I wondered
if the marrow transcriptome at TP4 contributed to the blood transcriptome at TP5.
To assess the significance of the overlap, I extracted the genes that were up-regulated
in TP4 of marrow. I then performed a sign-test (binomial test with probability of
success = 0.5) to see if those genes were more likely to also be up-regulated in the
TP5 of blood. The results were highly significant (p < 2.2 ∗ 10−16). I performed a
similar analysis for the down-regulated genes and found a similarly significant result.
As a control, I then took a comparison of TP6 and TP7 in blood for the same
up- and down-regulated genes and did not find an enrichment (p = 0.74). This
shows differential gene expression in marrow is reflected in blood with a time lag.
Further, since blood had many fewer significant genes that marrow, I also conclude
that gene expression in blood is buffered against differential expression in response
to pyrimethamine compared to marrow.
After investigating the changes in expression over the course of the experiment
with each time point considered separately, I next performed differential gene expres-
sion as a function of drug treatment using the three groupings described in Figure 4:
pre, post, and inter. In the marrow and blood, there were 6483 and 0 differentially
expressed genes, respectively, at an FDR=5%. This result is qualitatively similar to
the analysis performed by time point, where marrow had many more significant genes
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Figure 10: Clustering of the significant genes as a function of time. (A)
Marrow and (B) blood gene expression levels clustered by time point. Red (blue)
lines indicate the genes that clustered together and were up-(down-)regulated in the
two transcriptomes.
that blood.
In the metabolome, the two different columns, AE and C18, had 1,452 and 3,011
differentially abundant features (out of a total of 15,728 and 20,767, respectively).
While feature resolution for metabolomics has grown by orders of magnitude in re-
cent years, the ability to assign putative compound names to each of these detected
features has lagged behind. As a result, no pathway analysis was performed for
these many differentially abundant features. However, the large numbers of adducts
that are different across the drug treatment regimen leads me to conclude that the
metabolome has been dramatically affected by pyrimethamine. A notable feature of
the metabolome is the absence of any adducts with a mass-to-charge (m/z) ratio that
corresponded to the administered drug, pyrimethamine.
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2.4.6 Gene set enrichment analysis
After identifying the differentially expressed genes, I then performed gene set en-
richment analysis on the two datasets, marrow and blood. 1 The most significantly
enriched pathway in the marrow for the pre-versus-post comparison was the KEGG
pathway of one-carbon cycling by folate; this was also the second-most significant
pathway in the pre-versus-inter contrast (Figure 11A). The enrichment of this path-
way shows that when the enzyme DHFR is inhibited by pyrimethamine, there is a
subsequent down-regulation of the other genes in this pathway. Interestingly, genes
in this pathway are not enriched in the blood.
Figure 11: KEGG gene set enrichment plots for four representative path-
ways. The bar that transitions from red to white to blue indicates the value of the
t-statistic; red signifies genes that are highly expressed in either the post- or inter-
drug treatment, whereas blue signifies genes that are highly expressed in the pre-drug
treatment. Each vertical black line is the location of a gene in the specified pathway.
(A) One carbon cycling by folate; (B) oxidative phosphorylation; (C) cell cycle; (D)
apoptosis. n/s signifies that the enrichment was not significant at FDR=5%.
Pyrimethamine inhibits DHFR which then leads to decreases in folate cycling
1In spite of the fact that there were no significant differentially expressed genes in the blood,
gene set enrichment is still possible using the pre-ranked list method of GSEA.
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and reductions in the folate pool. Folate, which plays an essential role in nucleotide
synthesis, also is needed for energy generation in the mitochondria (Figure 11B). It
comes as no surprise, therefore, that genes in the oxidative phosphorylation pathway
are also down-regulated after pyrimethamine treatment both seven days as well as
30 days after administration, and the down-regulation occurs not only in the marrow
but also in the blood.
As mentioned above, folate is a required cofactor for the synthesis of some nu-
cleotides, as well as the methylation of proteins and amino acids. With insufficient
production of nucleotides, the rapidly dividing cells of the bone marrow would be
unable to proceed through mitosis at normal rates, or cell division may stop com-
pletely. I report that both seven days and 30 days after pyrimethamine treatment,
genes related to cell-cycle are down-regulated in the marrow (Figure 11C). Since the
blood is mostly a post-mitotic tissue (i.e. most cells are terminally differentiated)
there is no significant enrichment of cell-cycle-related genes in this tissue.
Lastly, with an inability to produce sufficient energy and/or a stalling of cellular
division, a cell may enter a state of apoptosis. If this were the case, there should be
an up-regulation of genes related to programmed cell death, which is what is observed
(Figure 11D).
2.5 Discussion
2.5.1 Methodology for data analysis and integration
In this chapter, I laid the groundwork for the statistical and analytical techniques
that allowed me to integrate the various data-types available for this experiment.
In applying these methods to a group of macaques that will serve as a control, I
demonstrated that pyrimethamine, a common anti-malarial drug, has lasting effects
on both the blood transcriptome as well as the bone marrow.
In the variance component analysis of this study, I was able to account for much of
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the variance in the transcriptome data especially after removing low abundance tran-
scripts (Figure 2B). In spite of the ability to account for such a substantial proportion
of the variance, the residual variance is still around 25-30%. This residual variance
may be due to many factors. Besides the natural variability in gene expression and
other unmeasured biological covariates, this residual variance may be due to primate-
specific responses to the AMD treatment; that is, there may be an individual-by-
drug-treatment interaction effect in which one primate may have a stronger response
to the AMDs due to its underlying genetic background. In a similar experiment
in Drosophila, we found that there was a strong genetic main effect (analogous to
subject, in this case), as well as a moderate gene-by-environment interaction in the
transcriptome. And the effect of the environmental perturbation was relatively small.
While the interaction effect cannot be measured in this study due to lack of replicates,
this proposed explanation is consistent with the observations in this study.
2.5.2 Between-subject effects
In the exploration of the various data-types, I showed that the variance of both the
transcriptomic datasets as well as the CBC data have very strong between subject
effects. This finding underscores the importance of repeated measures to increase
statistical power in differential gene expression analysis.
The high level of within-individual conservation compared to between-individual
differences is under-appreciated in the analysis of many biological data types. The
importance of repeated measures (and subsequent inclusion of this term in the sta-
tistical model) is shown in my analysis in which I identify differential expression
with and without including animal in the model. Perhaps the most data-rich gene
expression studies with longitudinal sampling of individuals comes from the Storey
lab.[38] Without explicitly describing the inter-individual variation in gene expression
profiles, they implicitly control for it by looking at rates of change of profiles over
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the course of many days. Unfortunately, these kinds of profiles (and rates of change
thereof) depend critically on sufficient temporal resolution so as to be able to deter-
mine rates of change. In this case, there was not the required temporal density of
data that would have allowed for this kind of analysis. However, explicitly accounting
for the inter-individual variation was sufficient to resolve important patterns in the
transcriptome.
In spite of this high within-individual conservation of gene expression, there is
no analogous individual-wise clustering of the CBC when using the major cell types.
This implies that the genes that are differentially expressed across individuals are not
differentially expressed across blood cell types.
My approach to integrate the transcriptome and metabolome, principal compo-
nent regression, yielded a negative result. While I observed good correlations within
the datatypes (i.e. blood and marrow transcriptomes were correlated, and C18 and
AE columns for the metabolome were correlated), there was minimal correlation be-
tween the transcriptomic and metabolomic datasets. This finding was unexpected
given the connection between these functional molecular classes. It is important that
we do not have metabolomic data from the first two time points (i.e. there is no
pre-drug exposure). Since the greatest differences in the transcriptome were between
the pre- and post-drug groups, we are clearly missing important data that would have
shed light on the effect of anti-malarial drugs.
Between the CBC data and the transcriptome there was a similar lack of a clear re-
lationship between the features despite intuitive expectations otherwise. Upon further
consideration however, this lack of strong correlation between different technologies
demonstrates that these data types offer non-redundant information about the state
of the system, and adding additional data-types has the potential to increase our un-
derstanding of the system. If the metabolome could be perfectly recapitulated using
only the transcriptome, there would be no need to interrogate multiple data-types.
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The usage of BIT axes scores to reduce dimensionality and infer biological struc-
ture in RNA-seq data represents a new application of this statistical technique which
was originally developed for microarray datasets. Also, this is the first time that this
technique has been applied to a tissue other than blood. Based on the high level of
variance explained by the each of the first PCs (i.e. the axis scores) for marrow, it
appears that this method of data reduction is appropriate for marrow because it is
capturing biological signatures that differ across time and drug treatment.
2.5.3 Dysregualtion of gene expression
In the bone marrow, there were thousands of genes that were dysregulated as a func-
tion of the drug treatment. Genes with altered expression were enriched in biological
functions like one-carbon cycling by folate, oxidative phosphorylation, cell cycle, and
apoptosis. For the one-carbon cycling by folate, I anticipated that the host would
up-regulate genes in this pathway, especially DHFR, to compensate for the inhibition
caused by pyrimethamine. Contrary to my expectation, however, the genes in this
pathway were nearly uniformly down-regulated, suggesting that the cells sensed the
decrease in the substrate tetrahydrofolate, and reduces expression of genes involved
in its cycling.
In addition to the mitochondrial disruption that occurs in both the 7 days post-
drug and the > 30 days post-drug in BOTH tissues (blood and marrow), there are
numerous processes that are down-regulated in the marrow that relate to cell cycle
control and mitosis (e.g. DNA replication, condensed chromosome, G1-S transition
of mitotic cell cycle). This result is expected considering that the bone marrow has
many more cells undergoing cellular division compared to the blood, which has mostly
post-mitotic cells.
Through this thorough examination of the effects of pyrimethamine using high-
throughput transcriptomics, I have identified numerous molecular pathways that are
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dysreguated in response to pyrimethamine treatment. Furthermore, I have shown
that this dysregulation of some pathways persists for at least a month after the last
drug dose, much after the drug should have been cleared from the blood plasma.
Further questions about the possible dysregulation of host molecular pathways
remain unanswered. For instance, pyrimethamine is often given in combination with
another AMD usually the sulfonamine sulfadiazine. However, this medicine is often
given with folinic acid which helps to reduce the level of folate deficiency and the
downstream negative effects. In this study, we did not investigate whether folinic acid
supplementation could abate or completely remove the negative host effects produced
by pyrimethamine administration.
The results of this study are particularly important given the recent trend of
re-purposing pharmaceuticals for the treatment of other diseases. Considering that
pyrimethamine has potential as a treatment of amyotrophic lateral sclerosis (ALS),
these results and datasets represent an important asset to the scientific community.
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CHAPTER III
HOST GENE EXPRESSION ALTERATIONS DURING
MALARIA INFECTION
3.1 Abstract
To address gaps in the understanding of host response to relapsing malaria, we per-
formed a 100-day experiment that spans one primary infection and two relapsing
infections of Plasmodium cynomolgi in the non-human primate Macaca mulatta.
Previous studies have examined the differences in gene expression that occur in
hosts in response to malaria infection. This project represents that first time that
host gene expression has been monitored across multiple peaks of parasitemia using
digital gene expression quantification (RNA-seq).
Leveraging the power of this experimental design, I found qualitatively different
gene sets enriched between the three parasitemia peaks in light of the vast differences
in host clinical parameters between the first and subsequent malaria infections.
After performing differential gene expression followed by gene set enrichment anal-
ysis, I found that previously-identified immune pathways are altered in the host in
response to the primary parasitemia, but not in the relapsing time points. There
are also remarkable differences in the systemic lupus erythematosus (SLE) and heme
metabolism pathways. These findings demonstrate that relapsing and primary par-
asitemias are qualitatively different. I additionally identify differences in host blood





The Malaria Host-Pathogen Interaction Center (MaHPIC) is a multi-institute collab-
oration consisting of a number of different experiments designed to address specific
gaps in the understanding of underlying dynamics of malaria infection by perform-
ing and integrating a number of unique molecular and cellular analyses. In this first
infection experiment, Macaca mulatta was infected with Plasmodium cynomolgi to
understand host and parasite changes across three peaks of parasitemia: a primary
parasitemia followed by two relapsing parasitemias.
3.2.2 P. cynomolgi as a model for P. vivax
Plasmodium vivax, the most common malaria parasite outside of Africa, has received
relatively less attention than its more pernicious cousin P. falciparum. In spite of
its perception as a less-deadly malaria parasite, P. vivax is an important cause of
morbidity and mortality in humans.[100]
Due to ethical considerations, it is difficult to receive approval to infect humans
with P. vivax and observe high parasitemias and subsequent relapses of malaria. P.
cynomolgi, a malaria parasite that also produces hypnozoites, inoculated into M.
mulatta serves as a good model for relapsing P. vivax malaria in humans.
P. cynomolgi is a well established model for P. vivax [104, 128, 33, 45] and re-
cently has been used to study host responses to co-infections with malaria and other
organisms.[77, 155] Only one previous study in macaques (2005) considered the host
response to relapse on a transcriptome-wide level.[163] In this study, they report
many genes that respond differently across the various peaks, but due to lack of suf-
ficient sample size, they do not determine statistical significance of their findings.
They use a unconventional gene set enrichment approach that only broadly impli-
cates immunological defense responses but not cytoskeleton pathways in response to
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infection. Consequently, a clear understanding of the difference in host response to
primary compared to relapsing parasitemias is yet to be established. In the interven-
ing years, vast improvements in functional annotations of primate genomes have been
achieved and should allow for more detailed analysis of gene set enrichment.
3.2.3 Hypnozoites and relapse
Unlike P. falciparum, P. vivax can produce dormant liver stage parasites known as
hypnozoites. These dormant hypnozoites can be reactivated in response to exter-
nal cues; parasitemias caused by reactivation of these dormant forms are known as
relapses. As a result of having a relapse-causing hypnozoite stage, the parasite pro-
longs the duration that it is in the blood stage during which it could be transmitted
to a mosquito, a necessary step in the completion of its life cycle. While secondary
parasitemias increase the probability of continued transmission, another potential
evolutionary benefit for the production of relapsing infections is the increasing of the
complexity of infection (COI), a measure of the number of different parasite strains
within a host at a given time. Having a greater COI offers the opportunity for ex-
change of genetic material between unique parasite strains during recombination in
the mosquito vector.[103] Studies of natural genetic variation of other hypnozoite-
forming species have not been performed.
3.2.4 Host gene expression in malaria infection
Previous work in host gene expression has focused on various aspects of the host re-
sponse: susceptibility and response to severe malaria,[96, 87] gene expression changes
during placental malaria,[20, 99] variation in response due to infection history (naive
versus persistent infection),[106] differential host outcomes, mild versus severe malaria,[78]
and general trends in expression during infection.[67, 57, 163]
In human malaria infections in West Africa, Idaghdour et al reported that the
blood transcriptome showed evidence of up-regulation of certain gene sets including
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immune-related pathways: TNF pathway, chemokine signalling, NOD-like, Toll-like,
and Fc-γ mediated phagocytosis.[67] Also, the PPAR signalling pathway and the in-
sulin receptor signalling pathway were up-regulated suggesting altered host metabolic
state in response to infection. Down-regulated were pathways like aminoacyl-tRNA
biosynthesis and ribosome, which signifies a reduction in translation in the cell pop-
ulation as a whole.
Kwiatkowski and colleagues reported an increase in expression of neutrophil-
related genes during acute malaria.[57] This increase in neutrophil-related genes was
accompanied by an increase in the absolute abundance of neutrophils but was not
completely explained by it. Type-I interferon has been found to be associated with
malaria infection, but reports differ with respect to the direction of effect.[96, 78, 20,
94] While previous expression profiling studies have assessed changes in response to
malaria infection, there is a lack of enquiry concerning differences between primary
and secondary infections.
Many of the previous studies were either performed in humans or mice. As men-
tioned above, there are certain experimental limitations when working with human
malaria infections. For instance, there is likely to be high variance in expression data
due to confounding factors like co-infection with other diseases and different envi-
ronmental exposures like diet and life-style. Because of the large amount of variance
coming from unexplained sources, large sample sizes are needed in human studies.
The benefit of using a mouse model is the ability to both tightly control any poten-
tial confounding factors as well as allowing the subjects to progress to severe levels
of clinical malaria.
Two potential drawbacks of using a mouse model are the genetic homogeneity
(due to inbreeding) of the mouse strains and the evolutionary distance between hu-
mans and mice. The high genetic homogeneity of the mice introduce the possibility
that results are specific only to the strain under study and are not generalizable to
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the population, as a whole, not to mention inability to infer human responses. The
importance of inter-individual variation due to underlying genetic differences in terms
of host response to malaria was underscored in a recent study.[67] In this large expres-
sion quantitative trait locus (eQTL) study in an African population, Idaghdour and
colleagues identified alleles that altered gene expression in a malaria-status-dependent
manner. That is, the allele did not significantly effect the expression of a nearby gene
in the absence of malaria, but did effect the expression in the presence of an active
malaria infection. This finding demonstrates individual-specific responses to malaria.
A second disadvantage of using mouse models to infer human response to malaria
is the evolutionary distance between humans and mice is great. Humans and pri-
mates are sufficiently related that some of the same species of Plasmodium can infect
members of the two groups (e.g. P. knowlesi which infects both humans and rhesus
macaques, and P. falciparum which infects both humans and Aotus monkeys). In
light of their genetic and immunological similarity, primates may offer greater insight
into human malaria response than other model organisms.
3.2.5 Host response to secondary malaria infections
Previous studies have documented great differences between host response to primary
versus secondary infection. In rhesus macaques, it has been observed that parasite
counts during primary parasitemia are much higher, and clinical measures of disease
(anemia, pancytopenia, multi-organ failure, etc.) are much more severe during the
first infection; subsequent parasitemias (both relapsing and recrudescent) were well-
controlled by the host.[163, 98]
Another observation that leads me to believe that the host response on the tran-
scriptional level will be qualitatively different in the relapsing parasitemias compared
to the primary parasitemia is that, in humans, clinical immunity is built over time,
further enforcing the belief that the host immune system becomes more adept at
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neutralizing the threat of harm from the parasite.
In spite of these observations which demonstrate vast differences between a first
and subsequent malaria episodes, a previous expression profiling study only identified
a single gene that was differentially expressed between episodes of severe versus subse-
quent mild malaria, which suggests that in spite of dramatic clinical differences, there
may not be differential response to relapsing parasitemias on the host transcriptional
level.[78]
3.2.6 Motivating hypothesis
In this chapter, I deeply profile the host transcriptome changes that occur in response
to malaria infection and explore whether there are qualitative differences between the
host response to primary and relapsing parasitemias.
Using differential gene expression analysis in series with gene set enrichment, I
will address the following questions. First, are there many genes differentially reg-
ulated between primary and relapsing parasitemias? Based on the results from the
aforementioned study, the null hypothesis may be correct. That is, the host tran-
scriptome may not differ between primary and relapsing parasitemias. However, if
there are many genes differentially regulated in the primary parasitemia that are not
dysregulated in the relapsing time points, that would constitute evidence that there
is a difference in magnitude and/or the quality of effect.
Based on the vastly different clinical outcomes of primary versus relapsing para-
sitemias, I do expect a difference in the magnitude of effect of differential gene ex-
pression. The question remains, however, whether the host response is qualitatively
similar between the two infection peak types. If the host response is qualitatively
similar between primary and relapsing parasitemias, I would expect to see similar
gene sets enriched with the differentially expressed genes. If the host transcriptional
response is qualitatively different between the two infection peak types, however,
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unique gene sets will be enriched.
In addition to gene set enrichment analysis, I also use two additional complemen-
tary methods, blood informative transcript (BIT) axis analysis and cell-type specific
gene expression, to profile the global alterations that occur in the transcriptome over
the course of the experiment. I will specifically contrast the activation of hematopo-
etic and immune-related pathways across the various infection peaks.
3.3 Methods and materials
3.3.1 Experimental design
The Malaria Host-Pathogen Interaction Center (MaHPIC) is an inter-disciplinary in-
vestigation that utilizes multiple data types to better understand the systems biology
of the complex host-parasite dynamics in the course of malaria infection. For this
malaria infection experiment, the design is as follows. Five male rhesus macaques
(Macaca mulatta; RFa14, RFv14, RIc14, RMe14, and RSb14) approximately 2 years
of age were profiled over the course of a 100-day experiment after being injected with
purified sporozoites of the species P. cynomolgi on day 0 of this control experiment.
Complete blood counts were performed daily by the Malaria core team members.
Before injection, the time point 1 (TP1) samples were taken by the Malaria core.
Then, on approximately days 20, 26, 53, 59, 89, and 96, blood and marrow samples
were collected for TP2-7, respectively (Figure 13). A sub-curative dose (1mg/kg)
of artemether was given at TP2 to three of the five animals (RFa14, RFv14, and
RMe14) to stem the increases in parasitemia. At TP3 and TP4, all animals received
an 8-day course of artemether: day 1 (4mg/kg); days 2-8 (2mg/kg). At the end of the
experiment, all animals were given fully-curative doses of chloroquine. All aspects of
this study were all approved by the Institutional Animal Care and Use Committee
(IUCAC) of Emory University.
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3.3.2 Transcriptome analysis
Library preparations, read mapping, and expression quantification were all performed
as described in the previous chapter (Figure 12). Briefly, total RNA was extracted
from whole blood from samples taken across the 100-day experiment. Due to poor
RNA quality, one sample was not sequenced (RFv14 at TP2). mRNA was enriched
from total RNA using poly-dT beads. All library preparation was performed by
Dalia Arafat. Libraries were bar-coded and sequenced on an Illumina HiSeq2000 in
the Yerkes Genomics Core led by Dr. Zach Johnson. After sequencing, reads were
mapped to a combined reference genome including host and parasite genomes; both
genomes were the most recent genomes and were obtained from the iRODS repository
from the MaHPIC project website. HTSeq was used to assign read counts for each
annotated gene. Finally, DESeq was used to calculate normalized expression values,
which were subsequently used for differential gene expression analysis.
3.3.3 Gene set enrichment analysis
After calculating the normalized expression values, a pseudocount of one was added
and the data were then log2-transformed. All genes with an average transformed
expression value below 3 were excluded from further analysis. This transformed
dataset served as input to the statistical software, JMP. Differential expression was
determined using an analysis of variance (ANOVA) test in JMP with animal as a
random effect and time as a fixed effect.
To perform gene set enrichment analysis, I chose the ranked gene list method and
used the Broad Institute’s GSEA v2.0.14 to perform enrichment analysis.[142] For the
contrasts of interest (TP1 against each of TP2-7), I performed gene set enrichment
using the KEGG pathways, Annotated gene sets, and GO terms. The t-statistic was
used as the rank metric and was obtained from the JMP output file. Gene sets with an
FDR < 25% were considered as significant in accordance with the recommendations of
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Figure 12: Analytical pipeline of gene expression profiling. After the 100-day
infection cycle, samples from all time points are then used to make paired-end, strand-
specific libraries for sequencing on the Illumina Hi-Seq. After sequencing, reads are
mapped to a combined reference genome and transcriptome. HTSeq is used to assign
expression levels to each annotated gene, and expression levels are then normalized
using the method suggested by DESeq. Subsequent down-stream analyses including
differential gene expression, cell type profiling, and blood informative transcript axes
profiling are then performed on the normalized expression values.
the GSEA software manual. Default parameters were used and included the removal
of gene sets with more than 500 or less than 15 genes.
To perform GSEA, a priori defined gene sets are needed. Since the rhesus macaque
is much less well-studied than the human genome, and considering that the majority
of genes in the macaque genome have well-conserved syntenic orthologs in the human
genome, I used the pre-existing human gene set annotations for this analysis. These
genes sets were obtained from the Broad Institute’s website.
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3.3.4 Blood informative transcript axis analysis
I employed blood informative transcript (BIT) axes analysis, which uses an a priori
defined set of nine blood axes, which are composed of genes (10 blood informative
transcripts per axis) that represent much larger groups of genes that covary across
blood transcriptional profiles.[114] This method has been described elsewhere.[102]
Briefly, I took the 10 BIT genes for each of the axes and calculated the BIT score for
each individual for both the blood and the marrow, separately, using the normalized
expression data. Then, I performed ANOVA to test for significant differences across
time after fitting the effect of animal. The first PC of most of the BIT axis explained
the majority of the variance for the 10 BIT genes.
3.3.5 Cell-type-specific gene sets
To identify the trajectories of specific blood cell types using the transcriptome data, I
downloaded lists of genes that were previously identified to be expressed in a cell-type
specific manner.[111] Gene sets were available (Additional File 2 from the manuscript)
for the following groups of cells: lymphocytes, B-cells, T-cells, CD8+T-cells, and
granulocytes. As a single descriptive metric of the trajectory of each sub-population
of cells, I performed principal component analysis (PCA) and used the first principal
component (PC1) as a relative measure of the abundance of the cell type. I then
performed an ANOVA to test for significant differences of cell-type abundance across
the experimental time points.
3.4 Results
3.4.1 Parasitemia across the 100-day experiment
Across the course of the 100-day experiment, blood was taken daily to quantify par-
asitemia using manual counting of infected RBCs on blood smears. The parasitemia
count data shows that the primary and subsequent relapse infections occurred at
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approximately the anticipated times during the experiment (Figure 13). Macaques
were injected with the sporozoites on day 0, and on day 12, all primates showed first
positive blood stages. The parasitemias continued to rise, and on day 20 the first time
point with evidence of parasitemia (TP2) was taken. To slow the rise of parasitemia,
three of the five primates (RFa14, RFv14, and RMe14) were given a single-day dose
of artemether to stem the rising parasitemia. Seven days later, the parasitemia lev-
els remained high for most hosts; a sample for TP3 was taken and subsequently all
surviving primates were given a full course of artemether, which quickly reduced the
blood-stage parasitemias to zero for all macaques. Primate RFv14 experienced severe
anemia as well as acute kidney failure, and supervising veterinarians made the deci-
sion to euthanize the animal on day 23 per IACUC-approved procedure. Time point
3 for this animal was taken immediately before euthanasia. The relapsing infections
occurred around day 60 for three of the four animals, and another relapse occurred
near day 90 for all four animals. Parasitemias for the relapsing infections were much
lower, a finding consistent with previous studies.[163]
3.4.2 Host blood cell parameters are altered by malaria infection
In addition to parasitemia counts, daily blood samples were used to perform complete
blood counts. A severe drop in all three major blood cell types (white blood cells,
red blood cells, and platelets) occur during the first and highest parasitemia in all
animals. Subsequent relapsing parasitemias are met with a much smaller response
from the host. Also note in Figure 14A that around day 20, there are two days
where the red blood cell levels for two primates (RFv14 and RMe14, represented by
light blue triangles and dark blue squares, respectively) are much lower than all other
measured readings. These two animals were given blood transfusions at this time
in an effort to prevent complications from severe anemia. As noted above, RMe14
successfully recovered, but RFv14 did not.
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Figure 13: Parasitemia levels across the 100-day infection cycle. Parasitemia
across the 100-day experiment. Approximate days of sampling are indicated by ar-
rows. At TP2 (pink), a single-day dose of artemether was administered. At TP3 and
TP4 (red), a full eight-day course of artemether was given (see methods for dosage).
Primate RFv14 was euthanized on day 23 due to renal failure. Note that a pseudo-
count of 1 has been added to the parasitemia counts before log transformation, and
therefore a log-parasitemia of zero is zero. This data was collected by the Malaria
Core principally led by Alberto Moreno.
As a general feature of the CBC data, I report that as in my previous analysis,
there are significant differences in many blood cell traits across the primates. Of
the 13 blood cell parameters measured, 9 were significantly different across the sub-
jects. Figure 14 shows lymphocyte count, one example of a cell type with differential
abundance. Considering that different animals have different blood cell parameters,
I wondered if such parameters could contribute to severe disease. For the one pri-
mate that experienced severe malaria-induced anemia (RFv14), I noticed that he
had lower levels of both mean corpuscular volume (MCV) as well as mean corpuscu-
lar hemoglobin (MCH). Since the corpuscle (i.e. RBC) is the specific cell type that
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Figure 14: Abundance of blood cell types across the 100-day infection cycle.
Cell abundances in whole blood of the major blood cell populations: (A) red blood
cells (RBCs), (B) white blood cells (WBCs), and (C) platelets. The black line is a
kernel-smoothed fitted line showing the trajectory of cell abundances. Data points are
colored by animal as in Figure 13. At the peak of the first parasitemia corresponding
to days 15-25, there is a precipitous drop in the numbers of all blood cell types, a
phenomenon known as pancytopenia. At the two subsequent relapsing parasitemias
(occurring around day 60 and day 90), there are smaller dips in the three blood cell
populations. (D) The distribution of lymphocyte counts by animal. Center line of
the diamond denotes the mean and the ends are the 95% confidence intervals. The
(E) mean corpuscular volume and the (F) mean corpuscular hemoglobin across the
100-day experiment. The animal that was euthanized due to severe malaria and renal
failure (RFv14, blue triangles) had lower levels of these two blood traits even before
patent blood stages.
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the malaria parasite invades and hemoglobin is the substrate upon which it feeds,
I suggest that one or both of these parameters may be important in severe malaria
pathology. This hypothesis is supported by a recent genome-wide association study
(GWAS) performed in humans, which shows that genomic loci that are important
in malaria resistance and pathology are enriched with SNPs that explain substantial
amounts of the variance in blood cell traits.[39]
3.4.3 Primary parasitemia extensively alters host gene expression
The variance components for this parasite-infection experiment are qualitatively sim-
ilar to what was observed in the control experiment; the effect of animal explains
40% of the variance while the effect of time point explains slightly more than the
control experiment at 25% (Figure 15A). This relationship is born out in the hier-
archical clustering of the principal components. Essentially, the samples cluster by
animal with the exception of the two time points of the first parasitemia, TP2 and
TP3 (Figure 15B).
When the 4,233 significantly differentially expressed genes are hierarchically clus-
tered, TP2 and TP3 do not cluster with the other samples (Figure 16A). Furthermore,
nearly all of the differentially expressed genes are either very up- or down-regulated
in one of these two time points. The time points sampled during the two relapsing
infections (TP4-7) cluster closer to the control time point (TP1) than they do to
either of the samples from the first parasitemia (TP2 and TP3). This result offers
evidence that there are qualitative differences between the transcriptional profiles of
the host response during primary versus relapsing malaria infections. In the volcano
plot for the contrast of TP1 versus TP2, there are many genes differentially expressed
(Figure 16B). In the TP1 versus TP4 contrast (that is, control versus first relapse
parasitemia), however, there are many fewer genes that are differentially expressed
(Figure 16C). After coloring the genes that are up- or down-regulated (red and blue,
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Figure 15: Summary of the blood transcriptome (A) The variance components
of the blood transcriptome. (B) Hierarchical clustering of the samples based on the
correlation of their principal component values.
respectively) according to the TP1 versus TP2 comparison, it is apparent that there
is little coherence in the host transcriptional response with respect to the direction
of expression between the primary (TP2) and secondary (TP4) parasitemias. This
result supports the alternative hypothesis that primary and relapsing parasitemias
elicit not only a different magnitude of response from the host, but also that there
is a qualitatively different host response. I note that there are still several hundred
genes that are dysregulated in TP4 (relapse) compared to the TP1 (baseline), albeit
to a lesser extent than in the first parasitemia (TP2).
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Figure 16: Differential gene expression analysis. (A) A hierarchically clustered
heatmap of the significant genes. Volcano plots comparing (B) TP1 versus TP2, and
(C) TP1 versus TP4. The dotted line near y = 2.3 is the cut-off for FDR=5%. Points
represent genes and are colored (if significant) by there direction of effect in the TP1
versus TP2 contrast, up-regulated at TP2 in red, and down-regulated at TP2 in blue.
3.4.4 Gene set enrichment analysis
To determine the biological pathways that are enriched with genes that are differ-
entially expressed across the three parasitemia cycles, I next performed gene set
enrichment analysis using pre-ranked gene lists.
The most statistically significant gene set enrichment that I identified between
the control time point (TP1) and the time point from the peak of the first infec-
tion (TP2), is the up-regulation of genes in the systemic lupus erythematosus (SLE)
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related pathway (Figure 17). This pathway contains two predominant gene types:
different histone variants and members of the complement pathway, suggesting an al-
teration in chromatin environment and immune response. The genes in this pathway
continue to be elevated at TP3, as well. These two time points correspond to the
highest parasitemias of the experiment. The enrichment of this curated KEGG path-
way has previously been shown in both mild and severe malaria compared to control
blood samples in the same direction as in our study.[67] Extending this finding and
further underscoring the importance of repeated measures across the course of infec-
tion cycles, I found that genes in this pathway are very significantly enriched with
genes that are down-regulated at time points subsequent to relapsing infections (TP5
and TP7). The tight co-regulation and extreme responses of this pathway during
malaria infection support the need for further targeted experimental work on these
genes.
The heme metabolism pathway (KEGG porphyrin and chlorophyll metabolism) is
up-regulated in TP3 compared to TP1, but TP2 does not have this same enrichment
(Figure 18). This may be occurring because of one of two non-mutually exclusive
mechanisms. First, since artemether, the anti-malarial drug (AMD) given at time
point 2, has the property of generating free radicals and reactive oxygen species
especially when in proximity to a heme group catalyst, it may be that the artemether
is destroying the heme group. The cell would then work to replace the lost heme by
synthesizing more of it. A second mechanism that would explain the increase in heme
production enzymes would be that the malaria-induced anemia has stimulated the
production of more red blood cells. As a result, the red blood cell precursors would
have the enzymes necessary for the production of heme. I believe that the latter
mechanism is correct for many reasons. Firstly, mature red blood cells lack a nucleus,
and so even upon sensing a decrease in the level of functional heme in the cell, they
would be unable to increase the abundance of the transcripts in the heme production
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Figure 17: Cycling of the SLE-related pathway. (A) Gene set enrichment
plots of the systemic lupus erythematosus (SLE)-related pathway genes annotated
by KEGG. (B) The first principal component of the SLE-related pathway plotted by
time. TP2 and TP3 are enriched with genes that are up-regulated in the SLE-related
pathway. TP4 there is no significant enrichment. Then at TP5 and TP7 genes in
the SLE-related pathway are expressed in the opposite direction, that is they are
significantly down-regulated. TP6 is enriched with up-regulated genes.
pathway. Secondly, if the single-day dose of artemether at TP2 was strong enough to
have an impact on the pathway seven days later, then presumably the eight day course
begun at TP4 would have caused the same pathway to be dysregulated at TP5, which
is not the case. The CBC data shows malaria-induced anemia in all of the animals
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beginning around day 14 and recovery of RBC counts around day 25. TP3 was
sampled very close to the turning point; the rising levels of RBCs is consistent with
the hypothesis that RBC precursors in the blood are contributing to the transcript
pool and leading to the appearance of increased heme pathway transcription.
Figure 18: Gene set enrichments. For a selection of gene sets with significant en-
richment in at least one time point compared to control, a heatmap of the normalized
enrichment scores (NES), which describe the level of enrichment of each pathway.
Other immune-related pathways that are enriched include NOD-like receptor, Toll-
like receptor (TLR), and RIG-I receptor pathways. These signalling pathways are
most often associated with viral or bacterial infection, and their activation leads to
the release of various cytokines including type I interferons. These signalling pathways
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have been reported as altered in human malaria infection but this is the first report
of genome-wide up-regulation in other primates. The Toll-like receptor pathway is
up-regulated at TP2, TP4, and TP6, which corresponds to the peaks of each of the
three parasitemias. Axis 5 (discussed in a subsequent section) includes TLR activity,
and is also all up at TP2, TP4, and TP6, which is consistent with neutrophilia at the
peak of infection.[59]
3.4.5 Cell-type specific expression
While gene set enrichment analysis offers important insights into the underlying host
pathways that are activated in response to malaria infections, differences in expression
profiles may be, at least in part, due to differences in cell-type abundance. To explore
the changes in host immune cell abundances I used a composite metric of cell-type
abundance (the first principal component of genes that exhibit cell-type specific ex-
pression, see Methods), I estimated the relative changes in cell-type abundance across
the course of the experiment.
There were significant changes in both the B-cell and T-cell populations as a
function of malaria infection. The B-cell specific genes fell at TP2 and then recovered
at TP3 and continued increasing throughout the end of the experiment (Figure19A).
T-cell specific genes followed the opposite trajectory: TP2 had a much increased level
of T-cells, but at all subsequent time points (TP3-7), T-cell genes were reduced below
the uninfected time point (Figure19B). The increase in T-cells does not appear to be
related to changes in CD8+ T-cells (also known as killer T-cells) since the genes
of this specific sub-type do not follow the same trajectory (Figure19C). This is not
surprising considering that CD4+ T-cells (also known as helper T-cells) are usually
the more abundant T-lymphocyte; a CD4+ T-cell-specific gene list was not available
for this analysis. Yet another possibility for the lack of coherence for the CD8+ T-
cell cycling is that activated immune cells often leave the circulation and aggregate
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in peripheral tissues.
Figure 19: Cell-type specific gene expression across the experiment. The
general behavior in B-cells (A) and T-cells (B) is qualitatively opposite. CD8+ T-cells
(C) do not account for the extreme variation in the T-cell population.
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3.4.6 Blood informative transcript axis analysis
In addition to cell-type specific expression, I performed blood informative transcript
(BIT) axes analysis. This BIT axes represent underlying modules of co-expressed
genes that have been previously identified in numerous blood transcriptome datasets.
Many of the axes are enriched with previously determined functional annotations of
gene ontology.
I found that many of the BIT axes showed significant differences across time in
this 100-day infection experiment. Axis 2, an axis enriched with genes associated
with hematopoesis, is significant across time points without controlling for the effect
of animal (Figure 20A).
Axis 2 contains genes that are enriched in GO terms related to oxygen trans-
porter activity and wound healing. The human disease and abnormal mouse pheno-
types associated with this axis are hemolytic anemia and hematopoesis, respectively.
Up-regulation of axis 2 during the peak of parasitemia and consequently the times
of highest parasite-induced hemolysis is expected, and gives further support to the
functional coherence of this axis. Importantly, the axis analysis and the cell type spe-
cific expression analysis are complementary approaches which have captured distinct
aspects of the host response to the infection, hematopoesis and T-cell development,
respectively.
After controlling for the effect of animal (see methods), there were significant
differences in axes 3, 5, 7, 8, and 9; axis 2 became even more significant when removing
the effect of animal.
Another very striking finding is axis 3 (Figure 20B), which is annotated as being
associated with B-cell activation, behaves very similarly to the B-cell gene set (Figure
19A). This initial drop in B-cells at TP2 is likely due to the pancytopenia (that is,
thrombocytopenia, leukocytopenia, and erythrocytopenia) induced by the infection.
This finding lends further support to the ability of BIT axes to capture information
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Figure 20: Blood informative transcript (BIT) axes over time. All plots
except (A) show the BIT axis trajectory after removing the between-animal effect.
(A) Axis 2, hematopoesis-related (p = 0.0002). (B) Axis 3, B-cell activation-related
(p = 0.0032). (C) Axis 5, cytokine receptor activity (p = 0.0067). (D) Axis 7,
interferon signaling (p = 0.0085). (E) Axis 8, RNA-processing (p = 0.0045). (F) Axis
9, apoptosis-related (p = 0.0481).
about the immunological state of the host using a very small number of transcripts.
Previous studies have identified interferon pathway up-regulation during malaria
infection which I also observe here as demonstrated by increases in axis 7 (Figure
20D). Importantly, this interferon axis is down-regulated at TP4-7, further supporting
the conclusion that host response to relapsing parasitemias are qualitatively different
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from the primary peak. Lastly, axes 5, 8 and 9 appear to follow similar trajectories:
high at TP2 relative to the control, followed by a zig-zag pattern: down at TP3 and
then back up at TP4, the first relapse (Figure 20C,E,F). Inflammation and apoptosis
(axes 5 and 9, respectively) are likely a by-product of the immune response to the
malaria infection.
3.5 Discussion
3.5.1 Gene expression in a relapse
The vast differences in the gene set enrichment analysis as well as the BIT and cell-
type specific expression analyses demonstrate that there is a qualitatively different
host response between primary and relapsing parasitemias in this non-human primate
model of P. vivax infection in humans.
A previous study investigated the differences in gene expression between a pri-
mary and secondary malaria infection in humans.[78] (No baseline transcriptome was
reported.) Compared to our analysis, theirs was similar in size, yet they only found
one gene differentially expressed at an FDR of 5%. This lack of significantly differ-
ent expression profiles suggests one of two explanations: 1) either unaccounted for
sources of technical or biological variance or both prevented them from finding many
significantly differentially expressed genes; or 2) the host response to re-infection is
qualitatively different from the host response to reactivation of dormant hypnozoites,
that is, a relapse.
The former is most likely. One source of unaccounted for biological variation in the
aforementioned human study is differences in diet as well as co-infection with other
agents. A source of technical variance could be the difficulty of uniform treatment of
samples in the field.
However, the latter may also be true. Re-infection (or recrudescence, as it may
have been) with P. falciparum may truly elicit a completely difference host response
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than a relapsing parasitemia with P. cynomolgi or P. vivax due to the fact that
the parasites re-activated during a relapse are likely to be genetically similar (or
identical) to the parasites of the first infection. However, population level diversity
of P. falciparum is lower than for P. vivax, and so this is not the likely mechanism
that would explain the difference in response.
The present experimental design measured baseline expression for all genes across
the transcriptome and then across three parasitemia peaks for a total of seven time
points for each macaque. The previous study lacked an uninfected baseline measure
of the transcriptome, a shortcoming that may have decreased their statistical power
to detect differential expression. However, if a re-infection behaved similar to our
relapsing infection, the difference between the first and subsequent infections would
likely have been strong enough to detect.
3.5.2 Comparison with previous study of P. cynomolgi
The macaques in our study showed the first evidence of blood stage on day 12 for all
individuals with a peak being reached around day 20. While the day of appearance of
blood stage parasites is qualitatively similar to a previous study, it took more than a
week for parasitemias to reach their peak in our study, whereas peaks were reported to
have been reached by day 14 (2-4 days after first appearance) in a previous study.[163]
Also, the first relapse for most of our primates occurred between days 50-60, much
later than a previous study.
In this study, I was able to perform statistical testing to identify differentially
expressed genes, which were plentiful. In the previous study, statistical testing for
differential gene expression was not possible.
The hierarchical clustering of all samples in our study was qualitatively different
from a previous study in macaques[163]. This may be the result of different platforms
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for measuring gene expression (microarray versus RNA-seq). Furthermore, normal-
ization method in microarray has been shown to be important differential expression
analysis and subsequently in biological inference.[116]
Unlike the previous study, design included samples both at the peak of relapse as
well as seven days after the peak. This allowed me to identify that the SLE pathway,
which was up-regulated at the first peak of parasitemia, was actually down-regulated
in the recovery periods after the relapses.
Yet another difference between our study and the previous study was that they
performed gene set enrichment analysis on the groups of genes that hierarchically
clustered together. This has the effect of enriching for genes that are highly correlated,
which are also therefore likely to be enriched for the same function if we assume that
genes in the same pathway are co-regulated. This kind of gene set enrichment has the
effect of artificially reducing the p-values of the enrichments. In spite of this difference
in method, we both identify pathways important in hemoglobin metabolism.
3.5.3 Systemic lupus erythematosus (SLE) and immune related gene set
enrichment
The recapitulation of the increased expression of SLE-related genes in response to
malaria demonstrates that this primate model of malaria is a good representation of
what happens in the human body during an infection. However, my identification of a
subsequent down-regulation of many of the genes in this pathway at later times (TP5
and TP7) offers a new and important insight with respect to the immune fluctuations
that occur in primate hosts during malaria infection and recovery.
In the introduction, I discussed the selection for HLA-b53 locus which provides
protection against severe malaria and is highly prevalent in West Africa. But beyond
host adaptations to the parasite, we can also consider the host-parasite co-evolution.
For instance, SLE, an autoimmune disease, is much more prevalent in African women
outside of Africa than it is for European women. Furthermore, there is much more
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SLE susceptibility among southern European women (which until recently had higher
exposure to malaria) than among northern European women. Importantly, there are
relatively very few reported cases of SLE in African women who currently reside in
malaria-endemic regions. I hypothesize, therefore, that chronic infection with the
parasite modulates the host immune system. And in the absence of such modulation,
the over-active immune system leads to the autoimmune destruction of some of the
host’s own cells.
A recent study in humans found evidence for a genotype-by-malaria-status inter-
action effect on the gene expression.[67] This provocative result provides a poten-
tial mechanism which could explain the high rates of SLE among African-American
women compared to European women and African women remaining in malaria-
endemic regions. Specifically, malaria infection may be modulating gene expression
networks of individuals whose genomes have adapted to a malaria-endemic environ-
ment. This finding is important in light of the fact that African-American (AA)
women have much higher levels of SLE than European-Americans (EA). I, there-
fore, hypothesize that the SLE of AA women is possibly due to co-evolution with
the malaria parasite in an attempt to modulate the negative impacts on fitness of
infection.
Further support of the importance of the SLE pathway in malaria infection is found
in a mouse model of SLE.[156, 157] In these studies, mice with susceptibility to lupus
(due to genetic polymorphisms) protected mice from cerebral and placental malaria.
Both of these finding are consistent with a protective effect of SLE against reduction of
reproductive fitness due to severe malaria. Yet another interesting connection between
malaria and SLE is the use of anti-malarial drugs in the treatment of SLE.[22, 71]
We are currently pursuing a further bioinformatic analysis to substantiate the
link between SLE and malaria. Specifically, we will compare genome-wide associ-
ation studies (GWAS) from both malaria susceptibility studies and SLE studies to
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determine if there are co-enrichments in the significance levels of SNPs or closely
linked genetic loci.
3.5.4 Hematopoesis
In my analysis, I observed an up-regulation of the hemoglobin production pathway
(KEGG porphyrin and chlorophyll pathway) at TP3. This hemoglobin production
could be up-regulated due to either parasite-induced anemia and/or artemether bind-
ing to heme groups and causing localized damage. I believe that this up-regulation is
due to the parasite-induced anaemia and not due to off-target artemether destruction
of RBCs.
Axis 2, which is enriched with genes important in hematopoesis, was most highly
up-regulated at TP3. While the animals received a single-day dose of the AMD
artemether seven days before this sample was taken, I do not believe that this al-
teration in RBC genes was related to the drug dose. This is because at TP4, the
macaques received a full eight-day course of artemether, and TP5 was taken near the
end of the treatment. No similar up-regulation of the hematopoetic axis was apparent
in TP5.
3.5.5 Cell type deconvolution of the samples
Blood is a heterogeneous tissue that is composed of many different kinds of cells:
RBCs, platelets, and many subtypes of WBCs, each cell type having a characteristic
expression profile. In a sample of blood, the proportions of each cell type would have
a great impact upon the gene expression profile. One way to determine and account
for differences in cellular composition is to perform sample deconvolution, which is
a computational method whereby the proportion of cell types are estimated based
on expression profiles. In our analysis, we did not perform cell type deconvolution
because we lacked RNA-seq profiles for the numerous cell types that would be ex-
pected to occur in the blood, and most cell type deconvolution software has only been
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written to be compatible with microarray expression data. Advances in this field will
allow for estimation of cell type proportions in our samples. Subsequently, we would
be able to use the cell type abundance data as a factor as well as a covariate in the
model. The infected time points may have differential abundance of certain immune
cell types. Additionally, even after accounting for cell type differences, infected time
points may have pathways that are differentially regulated. It is with this method,
cell type deconvolution, that we can tease apart the alterations that are occurring in
the host due to infection.
3.5.6 Individual-specific responses to malaria infection
In our study, we had measurements for only 5 primates, and yet we were able to
recapitulate many of the findings in a recent study in humans with more than an order
of magnitude more samples, a result that underscores the importance of repeated
measures. This increase in power to determine differential expression derives from
the ability to estimate individual-specific (and likely genetically controlled) levels of
expression.
In light of the differing responses of the hosts to the malaria infection (i.e. one
animal had to be euthanized and another also required a blood transfusion), I looked
for prominent features that co-varied with the severity of disease. The animal that
experienced the severe anemia and subsequent organ failure had the lowest MCH and
MCV in the first two weeks of the experiment before blood-stage infection became
apparent.
A recent study found that baseline hemoglobin levels were strongly inversely asso-
ciated with risk for multiple organ dysfunction syndrome (MODS).[158] In this study,
the animal that experienced the renal failure did not have the lowest hemoglobin levels
at baseline; he was approximately average for the days before evidence of blood-stage
parasitemia (days 0-12). As reported above, however, he did have much lower mean
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corpuscular hemoglobin as well as lower corpuscular volume. The importance of these
blood cell traits, especially MCH, is supported by a recent genome-wide association
study (GWAS) performed in humans, which shows that genomic loci that are im-
portant in malaria resistance and pathology are enriched with SNPs that explain
substantial amounts of the variance in blood cell traits.[39]
3.5.7 Caveats and limitations of this experimental design
While this experiment was able to unveil many important features of the host re-
sponse to relapsing malaria, there were aspects of the design that prevented more
precise dissection of mechanisms of response. For instance, there was a lack of tem-
poral resolution to precisely understand the timing of the hematopoetic activation
during the primary infection. From the CBC measurements, it is apparent that the
pancytopenia of malaria is most prominent during the first blood-stage infection peak.
Future studies could take more dense samples during the course of the first infection
peak. Here, we were limited in the number of samples we could take because there
was a maximum volume that we could extract from the primates over the course of
a given time period, and we were sampling for numerous high-throughput technology
cores.
3.5.8 Future studies
Lastly, I have herein left many lines of inquiry unexamined. First, the advantage of
using RNA-seq (this study) versus microarrays (nearly all previous studies) to profile
gene expression is that we can examine alternative splicing, antisense expression,
and differentially abundance of non-coding transcripts. While these kinds of analysis
may offer unique insights into the host response to malaria infection, it is difficult
to make functional inference about affected pathways. For instance, if there are 100
non-coding transcripts that I detect in the samples and 20 are differentially expressed
in the relapse peak but not the primary peak of parasitemia, what further inference
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can I make about underlying molecular mechanisms. This kind of analysis would
necessitate direct testing of importance of these transcripts by knock-down (say, by
RNA interference).
3.5.9 Conclusions
Many pathways that are differentially regulated in this study with macaques after
a primary malaria infection are qualitatively similar to those identified in humans
using much larger sample sizes; altered pathways (including RIG-I, NOD, Toll-like,
and complement pathways) have previously been identified in human studies as being
enriched during malaria infection, which supports the use of the model system for the
study of malaria in humans.[67]
Relapsing parasitemia peaks induce a much more restrained host transcriptional
response demonstrating that primary versus relapsing parasitemias was qualitatively
different.
Differential host clinical outcomes (e.g. severe malaria, death) appear to be related
to measurable blood cell traits, namely corpuscular volume and hemoglobin.
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CHAPTER IV
COMPOSITIONAL MODELLING OF PLASMODIUM
FALCIPARUM ACROSS THE INTRA-ERYTHROCYTIC
DEVELOPMENT CYCLE
4.1 Abstract
Microscopically, Plasmodium parasites take on three distinct states during progres-
sion in the intra-erythrocytic development cycle (IDC): ring, trophozoite, and sch-
izont. The number of distinct transcriptional states is less clear and is currently
still debated.[36, 83] Using a compositional modelling approach of discretized expres-
sion data, I estimated expression levels for a range of distinct transcriptional states
and simultaneously dissected the proportion of each asexual stage in each hourly
sample using previously published high-resolution expression data from Bozdech and
colleagues.[23] I discovered that there is a stable solution of three distinct transcrip-
tional states in the IDC, a result concordant with microscopic observations of infected
blood samples. Lastly, I used the results from this compositional analysis to identify
genes that are highly expressed in each distinct parasite life-stage, which will be used
in later analyses.
4.2 Introduction
4.2.1 Plasmodium gene expression
Beginning with the publication of the transcriptome of the intra-erythrocytic de-
velopment cycle (IDC) of P. falciparum, much effort has been invested to under-
standing the transcriptional dynamics of Plasmodium using high-throughput omics
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technologies.[23] In the first paper that profiled parasite expression in a transcriptome-
wide manner, Bozdech and colleagues showed that the majority of the parasite genome
is cyclically regulated across the IDC, with each gene having a characteristic peak.[23]
Using microarrays and probing the transcriptome hourly across its 48-hour cycle, they
were able to identify genes that had their peak at different stages of development (Fig-
ure 21A). Subsequently, numerous microarray and RNA-seq studies were published
that shed light on gene expression in Plasmodium.[122, 25, 58, 133, 43, 145, 24, 110, 89]
One important consideration for these kinds of expression analyses is that they
are interrogating a population of cells and not one individual cell. And due to natu-
ral variability in parasite development times, each sample would reflect the average
abundance of expression in a mixed population. A qualitatively similar problem
arises when trying to determine the relative contributions of various cell types of a
mixed tissue to the transcriptome. To determine the composition of a mixed sam-
ple of different cell types, various groups have implemented computational methods
to perform sample deconvolution.[121, 131, 54, 49, 55, 84] The underlying statistical
methodologies of these approaches are vastly different but have a similar underlying
goal: determine the relative proportions of each cell type in a heterogeneous sample.
Most of these previously implemented are deterministic and require a priori pure cell
expression measurements. The former is a short-coming because these models are
mathematically over-specified, that is, there are more equations than parameters to
estimate. A probabilistic algorithm would allow a greater exploration of the solution
space instead of deterministically arriving at a fixed solution. The latter is a difficulty
especially when there are an unknown number of cell types in the mixture.
Malaria researchers have implemented similar statistical methods for the math-
ematical deconvolution of mixed samples. These methods have allowed researchers
to both to get a clearer picture of the expression of the pure life stages and also to
dissect what is occurring at the level of transcription in the parasite over the course
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of an infection.
In a seminal work by Daily and colleagues,[36] researchers investigated the parasite
expression profiles of malaria-infected human blood using non-negative matrix factor-
ization (NMF), which is a spectral decomposition method that essentially performs
factor analysis on the underlying data.[26, 82] Within this analysis, three distinct in
vivo states were identified, and the genes partitioned by these three sets were enriched
for significant pathways and molecular functions. One drawback to NMF is that it is
not compositional; that is, there is no requirement that the components sum to one.
In this sense, it is more similar to a factor analysis decomposition.
A re-analysis of this data by another group accounted for batch effects of microar-
rays and employed a numerical approach which was more compositional in nature.[83]
In the Lemieux et al model, they assumed that all parasites in the blood were either
in an asexual or sexual stage and subsequently estimated the proportions of each
for each infected individual. Further, they used a maximum likelihood approach to
estimate the particular stage of the asexual cycle that most parasites were in. Impor-
tant to note, P. falciparum produces variable antigens which lead to sequestration of
later-stage parasites (i.e. trophozoites and schizonts) in the microvasculature. From
this re-analysis, all of the samples were abundant with ring stage asexual parasites,
as was expected from the biology of this parasite.
The method of Lemieux and colleagues likely produces a reasonable result because
the asexual parasites were all in approximately the same stage: rings. In other
species like P. vivax and P. cynomolgi, however, the trophozoite and schizont stages
do not sequester in the microvasculature, a behavior prominent in P. falciparum
due to its exporting of variable antigens, a molecular mechanism first described in
P. knowlesi.[64, 13, 141] Because their IDC position estimation is also more closely
related to a mixture model (which assigns each sample to one of a many possible
underlying groups), the implementation of this method would likely lead to very
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large confidence interval around the maximum likelihood estimate in a blood sample
from a species that did not sequester in later IDC stages. This is because in a species
that does not sequester in later stages, the parasites in a sample may be in very
different developmental stages.
The purpose of this study is three-fold. First, I explore a range of possible un-
derlying transcriptional states for P. falciparum during its progression through the
IDC. Next, I identify the number of discrete populations of life-stages in blood-stage
Plasmodium that optimizes the likelihood of the underlying data. Last, I determine
gene expression profile for each of the stages and identify genes that have their peak
expression in each stage, which will be used in later down-stream analysis. Based on
microscopic observations of the parasite, I hypothesized that there would be three
distinct transcriptional states in blood-stage Plasmodium, which would correspond
to ring, trophozoite and schizont stages. To achieve these aims, I have taken a full
compositional modelling approach to dissect the proportion of each asexual stage in
a given sample using the data from Bozdech et al, which contains expression mea-
surements from across the entire IDC.[23]
4.3 Methods and materials
4.3.1 Dataset
Bozdech and colleagues reported the hourly gene expression profile across the 48
hour IDC of P. falciparum. I downloaded this dataset from the supplementary data
available from the publication’s website. The expression levels were determined by
performing a competitive hybridization of the each time point against a pool of all of
the time points. Two time points were not present in the dataset (23h and 29h) for
unknown reasons. There were over 3000 genes with expression levels reported. This
represents the first and perhaps highest resolution genome-wide expression profiling
performed in Plasmodium for the in vitro IDC to date.
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4.3.2 Multi-dimensional scaling
To visualize the cyclical nature of the expression levels in the IDC, I performed a multi-
dimensional scaling of both the samples and the genes using R. First, the expression
data were downloaded from the supplementary data of the paper. Gene-by-gene
the expression levels were z-score transformed. Next, I calculated the Euclidean
distances between the feature of interest (either genes or samples). Then I employed
the cmdscale function using only two dimensions of scaling. The results were then
visualized in R.
d.trans.zscore <- dist(trans.data.zscore.Pf)
fit.trans.zscore <- cmdscale(d.trans.zscore,eig=TRUE, k=2)
4.3.3 Developing a method for life-stage deconvolution of mixed cultures
of Plasmodium using STRUCTURE
The aim of this study is to implement a statistical tool that allows for the estima-
tion of the proportion of each blood stage in a mixed population of parasites using
gene expression data. This problem is analogous to one encountered in population
genetics. In human population genetics, a given individual may be a descendant
of one or more historical populations, where each historical population has its own
population-specific allele frequencies for single nucleotide polymorphisms (SNPs) and
other genetic markers across the genome. Based on the allele frequencies of the his-
torical populations, we can estimate the likelihood that an individual came from a
given population using genome-wide genotypic information of the individual and the
historical populations.
In most cases, however, there is no access to the genotypes of the historical popu-
lations. However, if a sample is large and diverse enough, it is possible to estimate the
allele frequencies of the pure populations as well as the percent of the genome coming
from the historical population for each sampled (genotyped) individual. Analogously
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to gene expression data, we have many samples that are composed of a mixture of
cells in different stages of development. Each pure cell type (parasite development
stage) has a distinct expression profile with some genes expressed highly in one cell
type and at a lower level in other cell types. As in the population genetic problem,
we often do not have gene expression data for the pure cell types. In samples that
we wish to interrogate, some (unknown) proportion of cells comes from each of the
pure cell types. And the expression profile of the samples is a function of its cell type
composition multiplied by the expression profile of each pure cell type.
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Where n is the number of blood samples, m is the number of genes, and l is the
number of pure cell types.
The primary objective of this analysis was to implement a tool that allows for
the estimation of the proportion of each blood stage in a mixed population. Since
this cell type deconvolution problem is qualitatively similar to the problem of infer-
ring population structure using genome-wide genotype data, I chose to re-purpose a
widely-used software, STRUCTURE.[115]
To to make our continuous expression data compatible with STRUCTURE, I
performed a tertile discretization. For each gene, the top third of all samples were as-
signed a value of two; the middle third of all samples were assigned a value of one; and
the bottom third of all samples were assigned a value of zero. The discretized dataset
(46 hourly samples, 3719 genes) was then input into the STRUCTURE graphical user
interface. Another discretization was performed using a 10-80-10 division of samples;
qualitatively similar results were obtained.
I ran STRUCTURE for k=3-8 with three independent replicates each, setting a
random seed of 123 for reproducibility. Default parameters were used when available.
The program was allowed 2000 iterations for burn-in followed by 1000 Markov-chain
Monte Carlo (MCMC) iterations.
4.3.4 Identifying genes specific to each IDC life-stage
To find the genes that are specific to each distinct transcriptional state, I performed
the following workflow. For every gene, I calculated where its maximum expression
level occurred in the IDC. Then I identified the genes that had their maximum ex-
pression at each of the hours that had the highest proportion of each of the pure cell
types or had their maximum expression within one hour of the highest proportion.
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4.4 Results
4.4.1 Description of the dataset
To test the ability of this method to deconvolute samples of mixed cell type, I
used a previously published dataset of gene expression profiling across the IDC of
P falciparum.[23] All of the Plasmodium species profiled to date show a similar cyclic
progression of gene expression across the IDC (Figure 21A).
In panel B, hours 1 and 2 along with hours 43-48 all cluster in the bottom center.
This visual representation makes much more clear the relationship between the late
schizonts and the early ring stages in terms of their closeness of gene expression
profiles and serves to emphasize the cyclic nature of the IDC. Just as the samples
cycle in a predictable way through the IDC, so do the genes (Figure 21C). Note that
the coordinate space for multi-dimensional scaling is arbitrary; that is, the axes can
rotated around the origin without losing the relative distances between the points.
4.4.2 Implementation of the probabilistic deconvolution method
To achieve the aforementioned aims, I have taken a full compositional modelling
approach to dissect the proportion of each asexual stage in a given sample using the
data from Bozdech et al, which contains expression measurements from across the
entire IDC. I first transform the data from continuous to discrete values and then
employ a probabilistic framework to iteratively estimate both the fraction of each
life-stage in a given sample and also the expression level for each life stage. The
resulting gene sets will be used in subsequent analyses.
After discretization of the expression dataset, I ran STRUCTURE for k=3-8 using
three independent replications for each level of population number. For all values of
k > 3, I found that at least one of the solutions converged to the k=3 solution (Figure
22); that is, the solutions are essentially identical. This is important because given
the cyclic nature of gene expression, one of the possible outcomes would have been
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Figure 21: Expression profiling of the IDC of Plasmodium falciparum. (A)
A heatmap of the gene expression levels of genes (y-axis) for samples (x-axis) taken at
hourly intervals across the IDC. The extreme red color represents a 64-fold enrichment
over the pooled average across the IDC, whereas the extreme green represents a 64-
fold reduction over the pooled average. The left column of panel A shows microscopic
views of the various life stages. The top part of panel A contains abundance estimates
for each of the three unique cell type. Adapted from [23]. (B) and (C) Multi-
dimensional scaling (MDS) plots of the samples and the genes, respectively. Samples
are labelled by the hour at which they were taken.
convergence to a k=3 solution but with a phase shift. The fact that all of the k=3
results (as well as many of the k > 3 results) are of the same phase suggests that not
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only that k=3 is a stable solution for the number of unique cell types in the IDC but
also that we can assign the labels to the pure cell types based on our understanding
of the IDC progression.
Interestingly, for all k > 3, at least one of the simulations collapsed to the k=3
solution. This suggests that there are really three distinct populations of parasites
in the IDC. This hypothesis is consistent with microscopic observations which led
to the naming of three separate phases of the IDC: ring, trophozoite, and schizont.
Importantly, these estimates are strikingly similar to the microscopic stage estimates
(the top portion of Figure 21A).
Figure 22: Compositional modelling of the hourly expression data of the
IDC. The three panels represent the STRUCTURE output from k=3-5 from top
to bottom, respectively. Importantly, the k=4 and k=5 populations collapse and
converge to essentially the same solution as k=3. This demonstrates that k=3 is a
stable solution for the number of unique cell types in the IDC.
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4.4.3 Genes for each parasite stage
After the assigning the proportions of cell types present in each time point, I then
determined which sample had the highest abundance of each pure cell type. Hours
10, 25, and 39 had the highest proportion (nearly 100%) for each of the three cell
types which I have post hoc assigned the labels of ring, trophozoite, and schizont,
respectively. I then found the genes that had their peak of expression at those peak
samples or the sample time point on either side of it (i.e. 9-11 hours for rings, 24-
26 hours for trophozoites, 38-40 hours for schizonts). These genes were considered
stage-specific and were compiled into gene sets for use in future analyses.
Table 2: Parasite stage-specific genes.
IDC stage Number of genes putative enriched functions
Ring 426 ribosomal and ring-exported proteins
Trophozoite 405 DNA polymerase, helicase, mismatch repair
Schizont 184 glideosome- and rhoptry-associated proteins
There were 426, 405, and 184 genes in each of the stages of ring, trophozoite,
and schizont, respectively. The majority of all genes were annotated as coding for
conserved proteins of unknown function in plasmodb. While I did not perform a
significance analysis of gene set enrichments for these gene lists, the gene names
indicate that the genes with peaks in each of the stages are coherent for the biological
functions that occur therein (Table 2). For instance, genes with a peak in the ring
stage are annotated as ribosomal components and ring-exported proteins. In the
ring stage, the parasite has just successfully invaded a new red blood cell and up-
regulates the transcriptional program that had been turned off for schizogeny. In
the trophozoite stage, genes associated with genome replication and mitochondria-
associated proteins were present. In the trophozoite stage, the parasite the energy-
and resource-intensive growth and division that will take place in the schizont stage.
The schizont stage gene set contains genes that compose the glideosome and rhoptry,
which are essential for successful sinvasion of a new RBC after the schizonts rupture
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the infected red blood cells (iRBC) and release merozoites.
4.5 Discussion
Herein, I have shown that the asexual IDC of P. falciparum has a stable mathematical
solution of three distinct life stages, which correspond well to the stages observed
microscopically. I further compiled lists of genes that have a peak expression at each
of the three stages; these gene lists will be used in subsequent analyses.
While this probabilistic framework successfully recapitulated independent stage
assignment and therefore demonstrated its power, there are many caveats to this
method. First, it requires dense, high-resolution, time points throughout the IDC to
accurately estimate the gene expression of pure populations. Next, it is not easily
transferable from microarray to RNA-seq data, or even between different microarray
platforms. The Bozdech et al microarray dataset for P. falciparum was made using
a two-dye competitive hybridization.[23] As a result, it is difficult to use this dataset
together with, say, the dataset from Daily et al which used a single dye microarray
and therefore captured absolute expression levels.[37]
Concurrent to our development of this discretized method of inferring the rela-
tive abundance of parasite stages in a given sample, another group developed and
implemented a related method for Plasmodium.[70] In their method, they use linear
regression and a priori information about gene expression at each life stage to predict
the relative abundances. Superficially, their method and the one implemented herein
appear similar. However, there are many differences, including the primary objectives
of the work. In my work, I wanted to determine the number of distinct transcrip-
tional states in the Plasmodium IDC. In their study, the goal was to determine the
level of each life-stage in a mixed sample. My method has the advantage that it does
not make a priori assumptions about the number of classes, nor does it require a
priori information about the expression levels of each gene for the various parasite
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blood-stages. However, my method must iteratively estimate both the expression
levels of the pure populations and the composition of each of the samples. Addition-
ally, their linear regression method is based on the minimization of a least squares
term, which makes it sensitive to outlier genes with extremely different expression,
whereas my probabilistic, discretized model is not susceptible to such outlier genes.
As a disadvantage of my approach, in the discretization step, an essential part of my
implementation, information is lost. However, on aggregate across all genes, sufficient
information was preserved to recapitulate microscopic observations.
In conclusion, I have implemented a discretized, probabilistic method for gene ex-
pression deconvolution, and subsequently identified the three microscopically observed
parasite stages. Using these three populations, I extracted genes whose expression is
characteristic of each stage.
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CHAPTER V
GLOBAL SHIFTS IN PARASITE GENE EXPRESSION
PROFILES ACROSS AN INFECTION TIME-COURSE
5.1 Abstract
Gene expression of parasites from the genus Plasmodium has been extensively stud-
ied. However, to date, there has been little investigation of parasite expression over
the multiple infection cycles in an in vivo setting. Basic questions concerning gen-
eral patterns of gene regulation remain unanswered, especially concerning parasite
expression changes in response to anti-malarial drugs (AMDs) and across primary
versus secondary parasitemias. Herein, I examine parasite gene expression from P.
cynomolgi in rhesus macaque (Macaca mulatta) hosts. Clustering of parasite gene
expression demonstrate a distinct profile in the relapsing parasites compared to the
primary parasitemias, which includes a shift away from sexual stages in secondary
parasitemias.
5.2 Introduction
The gene expression program of the intra-erythrocytic development cycle (IDC) of
malaria parasites from the genus Plasmodium has been extensively studied in vitro
and has been shown to be robust to perturbation.[23, 24, 46, 97, 8] In vivo, how-
ever, the parasite needs to do more than just grow and divide especially in response
to differential host pressures (e.g. immune system). To cope with this dynamic
within-host environment, it would benefit the parasite to be capable of responding
appropriately. Furthermore, host clinical parameters and outcomes (e.g. anemia and
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organ failure) are much less severe in relapsing malaria episodes compared to the pri-
mary parasitemia. And whether host outcomes are associated with changing parasite
expression programs has yet to be investigated. Herein, I explore the parasite tran-
scriptional response of a P. cynomolgi infection of rhesus macaques (Macaca mulatta)
across a 100-day infection cycle and interrogate the correlation between the host and
parasite transcriptomes.
5.2.1 Expression profiling of Plasmodium
Bozdech et al paved the way for high-throughput analysis of gene expression in
Plasmodium.[23] Subsequently, it was shown that even under the selective pressure
of antimalarial drugs, the parasite shows an inability to alter its transcriptional
program.[46] Whereas most previous studies were in vitro, Daily et al looked at ex
vivo parasite expression from infected humans and found that there are only a few
distinct transcriptional states of the parasite in the blood.[36]
5.2.2 Relapsing malaria
While the human parasite P. falciparum is considered the most deadly malaria par-
asite, P. vivax causes close to 100 million cases of malaria each year. P. vivax is the
most common malaria parasite outside of Africa and pervades in tropical regions of
the Americas and the Asian Pacific. In spite of its impact on human mortality and
morbidity, this important human malaria parasite remains under-studied because of
its inability to grow in an in vitro culture system.[24] As discussed in a previous
chapter, it is not ethical to infect humans with P. vivax and follow the infection over
multiple peaks of parasitemia. As a result, malaria models in non-human primates
are used to gain insight in to the behavior of the human malaria parasites and their
within-host dynamics.
In this experiment, we use a P. cynomolgi infection of M. mulatta as a model
for P. vivax infection of humans, specifically with the goal of better understanding
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parasite expression changes during relapse. A relapse occurs when the dormant hyp-
nozoite form of the parasite, which exists in the host liver, is re-activated and causes a
distinct blood-stage parasitemia. The host clinical parameters are usually much more
mild during relapse compared to the primary infection. Sometimes the relapsing par-
asitemia produces no noticeable external symptoms, and the positive blood-smear is
the only indication of a relapse.[163]
5.2.3 Experimental design overview
Five male rhesus macaques (Macaca mulatta) were profiled over the course of a
100-day experiment after being injected with purified sporozoites of the species P.
cynomolgi on day 0 of this control experiment. Complete blood counts were per-
formed daily, and microscopic quantification of parasitemia was performed. Before
injection, the time point 1 (TP1) samples were taken. Then, on approximately days
20, 26, 53, 59, 89, and 96, blood and marrow samples were collected for TP2-7, re-
spectively. A sub-curative dose (1mg/kg) of artemether was given at TP2 to three
animals (RFa14, RFv14, and RMe14) to stem the increases in parasitemia. At TP3
and TP4, all animals received an 8-day course of artemether: day 1 (4mg/kg); days
2-8 (2mg/kg). At the end of the experiment, all animals were given fully-curative
doses of primaquine/chloroquine. Animal treatment was all approved by the IUCAC
of Emory University.
5.2.4 Motivating hypotheses
In a previous chapter, I showed that the host transcriptional response is highly altered
between primary and relapsing parasitemias. Now, I will investigate the differences
in the parasite transcriptome across multiple parasitemia peaks.
The motivation question for this chapter is: are there differentially expressed
parasite genes between primary and relapsing parasitemias? Previous experiments
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have shown that even when faced with severe artificial selection pressures (e.g. anti-
malarial drug administration), malaria parasites do not alter their transcriptional
profile.[46] Given the result from this previous in vitro study, I expect that the tran-
scriptional profile of the parasites will not differ over the two parasitemia peak types:
primary and relapse.
The alternative hypothesis is that the parasite transcriptional profiles differ be-
tween the primary and relapsing parasitemias. Evidence for this alternate hypothesis
would suggest that the parasite alters its transcriptional profile as a direct result of
having passed through the hypnozoite stage; alternatively the differential parasite
transcriptome may be an indirect result of attenuated host immune response to the
relapsing parasitemia. Support for the alternative hypothesis would be indicative of
yet another layer of complexity of transcriptional regulation in malaria parasites.
5.2.5 Chapter outline
In this chapter, I first describe the whole genome re-sequencing of the P. cynomolgi
strain that will be used in this experiment to confirm its identity. Next, I qualitatively
explore the structure of the expression profiles from the samples of the different time
points. Then, I perform differential gene expression analysis between the defined
experimental groups, and subsequently perform gene set enrichment to unravel the
differences in parasite expression across primary versus relapsing infection peaks. I
also explore the trajectories of selected multi-gene families.
5.3 Methods and materials
5.3.1 Whole-genome resequencing for Plasmodium cynomolgi B strain
To confirm the identity of the P. cynomolgi strain that would be used in the infection
experiment, a whole-genome resequencing of infected red blood cells was performed.
Genomic DNA was extracted from a whole-blood sample containing infected RBCs.
The DNA was sequenced on a HiSeq2000, and generated approximately 100 million
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paired-end reads. After inspecting the FastQC output files, there was no detectable
contamination of library preparation primers, and subsequently, the raw reads were
used in the mapping step.
Bowtie2 was used for mapping the reads to the P.cynomolgi reference genome with
both the –end-to-end and the –local alignment options, separately. The two methods
performed similarly in terms of the number of SNPs and InDels that they called.
As expected, the –end-to-end flag (which is more stringent in mapping) mapped
fewer reads and called fewer SNPs. However, because of the unfinished nature of the
genome, the –local option is most likely the better choice and was used for reporting
statistics in this report.
Depth of sequence coverage is an important metric because the deeper a region
has been sequenced, the more confident we can be in the genotype calls in that
region. 1 Even with only 6 million reads mapping to the P.cynomolgi genome,
93.4% (24,457,978/26,180,000*100%) of the nucleotides of the genome are covered
with >=20X sequencing depth.
Samtools mpileup was used in series with varscan to call the variants. These are
the options for VarScan. In essence, it requires, at least 8 reads of sequencing depth
to make a call at a given base. As stated above, nearly all of the genome meets this
threshold. Next, there must be at least 2 reads supporting the variant for it to be
called. This is an important threshold. Otherwise, sequencing error could dominate
the SNPs calls. Even though the error rate is only 0.001, with millions of reads, the
likelihood of SNPs would be high. The likelihood of seeing 2 reads support the same
SNP call by sequencing error is 0.0012/3, 2 and so we would only expect about 8
false positives over the whole genome. This suggests that most of the 1031 SNPs that
1Say an allele exists in the population at a frequency of 10%. If a region of the genome is only
covered by 10 reads, then the chances of the minor allele being missed is (.90)10 ≈ 0.35; whereas if
it had been covered by 20 reads, the chances of missing it are only (.90)20 ≈ 0.12.
2The average likelihood of a miss-called base squared for the two occurrences divided by three,
the probability of the two miss-called bases being the same (incorrect) base.
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we identified are likely true positives; these polymorphisms would be the standing
genetic variation in this particular strain.
5.3.2 Transcriptome analysis
Library preparations, read mapping, and expression quantification were all performed
as described in a previous chapter. Briefly, total RNA was extracted from whole blood
from samples taken across the 100-day experiment, and samples were dosed with
spike-in control RNA as described in a previous chapter. Due to poor RNA quality,
one sample was not sequenced (RFv14 at TP2). mRNA was enriched from total
RNA using poly-dT beads. Libraries were bar-coded and sequenced on an Illumina
HiSeq2000 generating approximately 50 million paired-end reads per sample. After
sequencing, reads were mapped to a combined reference genome including host and
parasite genomes. HTSeq was used to assign read counts for each annotated parasite
gene.
After quantification of read counts mapping to annotated genes, I then calculated
the total number of reads from each sample that mapped to an annotated gene. The
samples taken TP1 before infection should have no parasite reads. The number of
reads mapping to annotated parasite genes was, in fact, very low for these uninfected
time points (6-11,835; median 3,103). To only include samples with sufficient ex-
pression depth of coverage to accurately estimate expression, a minimum of 500,000
reads was required for a sample to be considered as having parasite expression. Ten
samples passed this threshold, and the library with the lowest read depth had at least
eight reads for 3,980 genes (≈ 70% of all genes).
In spite of the large variations in the Plasmodium transcriptome due to the cyclic
nature of expression across the IDC, the high correlation of gene expression across
most samples suggested that the robust library size estimation method of DESeq
would yield good scaling factors for making libraries comparable. To normalize the
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libraries, I used the DESeq method also used in previous chapters.[6]
5.3.3 Down-sampling methodology
Of the 10 samples with more than 500,000 uniquely mapping parasite reads, there
was wide variation in the read depth (approximate range 750,000-29,000,000). Reads
from all libraries were probabilistically down-sampled to the depth of the library with
the fewest reads. Briefly, I first determined the number of reads in the smallest library
(749,249). Then, for each library, I determined the number of reads. Then, for every
read in each library, the probability of it remaining in the down-sampled library was
equal to (number of reads in smallest library) divided by (number of reads in the
present library).
The R code is given below:
rm(list=ls())
expression.counts = read.table( "/home/kevin/work/Research/malaria/
Experiment04/Ex04_parasite_counts.txt", header=TRUE,sep="\t",row.names=1)
#remove columns (that is, libraries/time points) thhat have low read counts
expression.counts <- expression.counts[which(apply(expression.counts,2,sum)>500000)]
expression.probs <-t(t(expression.counts)/apply(expression.counts,2,sum))










#calculate number of reads in each column
total.reads <- apply(expression.counts,2,sum)
#calculate (or input) how many reads to sample
#by default, this finds the library with the fewest number
of reads and sets that as the value; this can be modified to fit needs.
reads.to.sample <- min(total.reads)
#loop over all of the libraries
for( i in colnames(new.counts))
{





















5.3.4 Differential gene expression
After observing the clusters of the time points into natural, discrete groups, I allowed
the groups to be those used for down-stream analysis. Four samples from TP2 were
grouped together (TP2), three samples from TP3 were grouped together (TP3), and
all the samples from the relapsing parasitemias (one sample each from TP4, TP6,
and TP7) were grouped together (secondary).
Then, one-way ANOVA was performed on these samples using the aforementioned
groupings. Unlike in the host expression analysis, the effect of animal was not used
as a random effect due to the small number of samples in the analysis.
5.3.5 Gene set enrichment analysis
To perform gene set enrichment analysis of the parasite gene expression data, we had
to first establish and populate gene sets. Since the majority of functional studies in
Plasmodium have been performed for P. falciparum, I investigated the P. falciparum
literature and made two different gene set groups: stage-specific gene sets, and GO
term gene sets.
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The previously-defined gene sets (Chapter DECONVOLUTION) for the three IDC
stages (ring, troph and schizont) were converted from P. falciparum to P. cynomolgi
using syntenic orthologous genes. Similarly, a list of genes that show gametocyte-
specific expression were extracted and converted to P. cynomolgi gene names.[164]
Gene sets of GO terms were downloaded for P. falciparum and converted to P.
cynomolgi, as well.
The following work-flow was used to obtain the syntenic orthologs between these
species. In PlasmoDB, all gene from P. cynomolgi were selected. Then, a step was
added: transform by orthology. Only genes that were annotated as syntenic or-
thologs between these two species were used. Then, the gene-correspondences were
downloaded and subsequently used to identify the P. cynomolgi orthologs for each
gene set.
Similarly, GO annotations for the entire genome were downloaded for P. falci-
parum and the same methodology was used to identify corresponding genes.
After generating the gene sets, the t-statistic from each of the three contrasts
were used to find gene sets that were coherently differentially regulated between two
or more of the groups. All possible pair-wise contrasts were investigated: TP2 versus
TP3, TP2 versus secondary, and TP3 versus secondary.
5.3.6 Gene group trajectories
Plasmodium helical interspersed sub-telomeric (PHIST) proteins play an important
role in host-parasite interactions during malaria infection. Some PHIST proteins
contain a red blood cell cytoskeleton binding motif, which may facilitate both the
trafficking of parasite proteins to the iRBC cell membrane, as well as the remodelling
and eventually the rupturing of the iRBC to release the infectious merozoites.[112, 91]
Tryptophan-rich antigens are another abundant multi-gene family in Plasmodium
species and which play a role in RBC invasion of merozoites.
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To characterize the expression of these multi-gene families over the time course of
the infection, I extracted genes in these families and performed principal component
analysis on each gene set, separately. I use the percent variance explained by the first
PC as a measure of the coherence of the expression (that is, co-expression) of each
family, and plot the value of the first PC for each sample over time.
5.4 Results
5.4.1 Whole-genome resequencing for Plasmodium cynomolgi B strain
Integral to the analysis of a transcriptomic dataset (using RNA-seq reads) is the pres-
ence of a high-quality reference genome for the species of interest. For P. cynomolgi
the reference genome was initially published in 2012 by Tanabe and colleagues.[143].
This group sequenced B strain, which is the P. cynomolgi reference genome available
in PlasmoDB and is the reference genome used herein.[11, 10]
Before the beginning of the 100-day infection experiment, I first undertook the task
of determining the identity of the P. cynomolgi strain that would be used. The goal
was to confirm that it was the same strain as that of the reference genome (B strain),
as parasites in culture have been observed to accumulate mutations in certain genes;
and sufficiently different genomes could result in poor mapping of transcriptomic
reads and therefore mis-quantification of expression.
To confirm the identity of our parasite strain, DNA was extracted from an in-
fected blood sample containing P. cynomolgi, and was then sequenced on an Illumina
HiSeq2000. Of the 109,375,524 paired-end reads, 6.3% of the reads map to the para-
site genome, using the –local flag3. To account for the reads that did not map to the
P.cynomolgi genome, I also performed a mapping of the reads to the Macaca mulatta
3Using the –end-to-end flag, 4.6% of the reads map to the genome. This discrepancy is occurs
because of the fragmented and incomplete nature of the genome assembly with which we are working.
The –end-to-end flag requires that the entire read map exactly to the genome. This is difficult for this
genome because there are many blocks of N’s, which the mapping software will count as mismatches,
and subsequently, a mapping, even though it is best, will not be considered because it is below a
certain threshold.
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genome. Indeed, approximately 94% of the reads map to the primate host’s genome,
which makes up for the difference.
The next step in confirming the strain’s identity is the calling of polymorphisms.
Since the parasite was isolated more than 30 years ago and has been maintained
through culturing in monkeys and subsequent cryopreservation, I anticipated that
there would be some divergence between the reference genome and the genome of the
parasites that would be used for inoculation. After mapping the reads to the genome,
I called single nucleotide polymorphisms (SNPs) using VarScan.[76] Remarkably, no
polymorphisms were detected in the 14 nuclear chromosomes (Figure 23).
Figure 23: Integrative Genome Viewer screen capture shows no polymor-
phisms. In the reads of this genomic region, there appear to be some sequence
polymorphisms which may be due either to acquired mutations due to passaging of
the parasite or sequence errors.
While the P. cynomolgi genome is relatively well-assembled, hundreds of large
contigs still remain unplaced, and within many of these unplaced contigs, there were
some called polymorphisms. Most of these contigs were difficult to place because
they are members of high-copy-number gene families and therefore share high levels
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of sequence similarity. In general, I do not anticipate that these polymorphisms in
unplaced contigs will qualitatively alter conclusions reached from this work. I note
that in other species (e.g. P. falciparum and P. knowlesi), the variable antigen
genes, which are responsible for immune evasion, represent a high-copy-number gene
family and therefore polymorphisms in unplaced contigs may be important in studies
performed in these species. In light of this result, I conclude that the P. cynomolgi
strain to be used in the 100-day infection experiment is genotypically very close to
the P. cynomolgi reference genome.
5.4.2 100-day experimental summary
As described in a previous chapter, the experimental infection of M. mulatta with
P. cynomolgi lasted 100 days, and spanned multiple parasitemia peaks for the four
macaques that survived the primary infection. Blood samples were taken daily to
quantify parasitemia using manual counting of the infected RBCs on blood smears.
The parasitemia count data show that the primary and subsequent relapse infections
occurred at approximately the same times across all animals supporting the consis-
tency of this model infection.
To stem the increasing parasitemias, a one-day, sub-curative dose of artemether
was given to three of the primates (RFa14, RFv14, RMe14) after taking the blood
and bone marrow samples for TP2. Seven days later, TP3 was taken (experimental
day 26 for all animals except RFv14 which had TP3 taken on experimental day 23
immediately before euthanasia). The relapsing infections occurred around day 60 for
three of the four animals (RFa14, RIc14, RSb14), and another relapse occurred near
day 90 for all four surviving animals. Parasitemias for the relapsing infections were
much lower than the primary parasitemia peak (between 101.5 and 104.5 and between
105 and 106 parasites per microliter, respectively). Note that the limit of detection is
approximately 103 parasites per microliter, and therefore readings below these levels
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have a high measurement error.
Figure 24: Parasitemia across the infection and transcriptome read depth.
(A) Parasitemia for each of the animals across the 100-day experiment. A single-day
dose of artemether was given to three of the primates (RFa14, RFv14, RMe14) at
TP2 (pink box), and full 8-day courses were given to all animals at TP3 and TP4
(red boxes). Parasitemia was much higher during the first infection relative to the
relapsing infections. (B) The number of reads mapping to each of the three sources of
RNA: the host (macaque), the parasite (P. cynomolgi, and the spike-in control RNA.
The highest levels of parasite RNA occur at TP2 and TP3, which corresponds to the
points of highest parasite density.
After collecting the samples, RNA was extracted from them and high-throughput
sequencing was performed. RNA-seq provides a digital read-out of the transcriptomic
100
state of a sample. While this technology offers many advantages over other gene ex-
pression quantification techniques, it also has an inherent limitation: insufficient se-
quence read depth prevents accurate quantification of gene expression genome-wide.
At low read depths, technical variance dominates, preventing the accurate estima-
tion of biological variation. With lower coverage, the coefficient of variation in the
expression measurements increases, subsequently decreasing power to detect differ-
ential expression. Furthermore, since most normalization techniques, including the
method used herein, are dependent upon the accurate estimation of many genes, I
have only included samples with at least a half-million parasite reads to ensure robust
inference of differential expression.
Based on this threshold, TP2 and TP3 have enough mapped parasite reads to ad-
equately quantify expression in four and three samples, respectively; in the relapsing
time points, there is only one sample each from TP4 (RSb14), TP6 (RSb14) and TP7
(RFa14) with sufficient read depth. As a matter of convention, I refer to the three
relapsing time points as secondary parasitemias.
5.4.3 Clustering of the parasites
After setting the sequence depth threshold for inclusion in the analysis (see Methods),
I determined the general topology of the relationship between the parasites at each
time point. A hierarchical clustering of the samples shows that samples from TP2
and TP3 cluster mostly within time point, and the relapsing samples (one from each
of TP4, TP6, and TP7) cluster separately (Figure 25A). Given that parasite sequence
depth ranged from about 750,000 reads to more than 29 million and that the relapsing
time points had few reads in comparison to TP2 and TP3, sequence read depth was
confounded with time point. To verify that the separate clustering of the samples
by time point was not due to differences in read depth, I coded a down-sampler in
R, which finds the sample with the fewest reads and subsequently probabilistically
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reduces the number of reads in all of the other samples’ libraries to that level. After
down-sampling, the relapsing time points cluster together, and samples from TP2
and TP3 still cluster in a similar way (Figure 25B).
Figure 25: Primary parasitemia expression profiles cluster away from re-
lapse profiles. (A) A heatmap of ten libraries with sufficient parasite read depth to
be considered expressed. The samples from the first parasitemia peak (TP2 and TP3,
in red and gold, respectively) hierarchically clustered mostly within time point. The
deepest branch in the clustering is between the relapsing parasite profiles (light blue),
and the primary parasitemia samples. (B) Same as in (A) but using the down-sampled
read counts for each library.
After defining the three groups of parasite samples (TP2, TP3, and secondary),
I explored the general correlation between genes in each group. In general, all three
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groups had strong linear correlations with each other (Figure 26). The secondary
time points, however, have a subset of genes that are below line of identity (x = y,
Figure 26B,C). The genes that are down-regulated in the contrast of secondary versus
TP2 (Figure 26B) are colored in black. There is a large overlap of these genes with
genes down-regulated in the contrast of secondary versus TP3 (Figure 26C).
Figure 26: Correlation of average expression between experimental groups
across all genes. (A) TP3 versus TP2, (B) secondary versus TP2, and (C) secondary
versus TP3. Non-parametric density gradients are overlaid in colored lines. Genes
that show a down-regulation in the secondary infection relative to TP2 are colored
in black; all other genes colored in grey
103
5.4.4 Differential gene expression across parasitemia peaks
After the initial exploratory analysis of the parasite expression dataset, I performed
differential gene expression to identify genes that are differentially regulated across
the three peaks of parasitemia. Between TP2 (peak of parasitemia during first blood-
stage infection) and TP3 (still during the first blood-stage infection) there are nu-
merous differentially expressed genes (Figure 27A). However, the vast majority of
the genes that are found to be differentially expressed are altered when comparing
the secondary infection time points to those of either TP2 or TP3 (Figure 27B,C).
Significant genes are colored by up- or down-regulation (red or blue, respectively)
in secondary parasitemias relative to TP2 (B). In the plot of secondary versus TP3
(Figure 27C), many of the colored genes maintain both directional coherence and
significance. Next, the nature of these genes that are down-regulated in secondary
parasitemias was investigated.
5.4.5 Gene set enrichment analysis for Plasmodium cynomolgi
The primary objective of this study was to elucidate the differences in the parasite
transcriptional state between primary and relapsing peaks of parasitemia. In the
previous section, numerous genes were identified that fit this criteria. In this section,
I investigated the functional enrichment of the shifts in gene expression by performing
a gene set enrichment analysis of both life-stage-specific gene sets as well as annotated
GO gene sets.
In the ring and trophozoite life-stages, there is a subtle yet significant up-regulation
in the relapsing (secondary) parasitemias compared to either of the primary par-
asitemia groups (TP2 and TP3) (Figure 28). Much more distinct is the down-
regulation in the relapsing time points of both the schizonts and gametocytes. This
down-regulation of gametocyte-specific genes in the secondary infection time points
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Figure 27: Volcano plots showing the magnitude and significance of differ-
ential gene expression across the three experimental groups. (A) TP3 versus
TP2, (B) secondary versus TP2, and (C) secondary versus TP3. The the significance
level of the difference (-log(p-value), y-axis) is plotted against the log-fold change in
expression (x-axis). Significant genes are colored by up- or down-regulation (red or
blue, respectively) in secondary parasitemias relative to TP2 (B).
demonstrates that there is a clear difference in the relative abundances of sexually-
committed parasites circulating in the blood during relapse.
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Additionally, from the bottom panel of the enrichment plots, I infer that gametocyte-
specific genes reach their peak at TP3, since they are up-regulated at TP3 with respect
to both TP2 and relapsing time points. Importantly, after samples were taken at TP2,
three primates were given a sub-curative, one-day dose of artemether. TP3 was then
taken seven days later. The two samples (of the three samples at TP3 for which there
is parasite expression data) in which the primate did not receive the sub-curative
dose of artemether are the ones that have the highest gametocyte expression. The
sample from the primate which did receive the sub-curative dose of artemether shows
a parasite expression profile much more similar to those of TP2 than of the samples
from TP3 that did not receive the AMD. What caused the shift in relative abundance
from asexual to sexual stages from TP2 to TP3 is unclear, but may have been due to
either sustained high densities of parasites in the blood, or host factors. The exact
molecular mechanism by which the parasite controls cell fate determination is yet
unknown.
5.4.6 Effect artemether on parasite life-stage abundance
To investigate the effect of the anti-malarial drug artemether on the parasite expres-
sion profiles, I used the life-stage specific genes to contrast the samples at TP3: one
which came from an animal that was treated with artemether (RFa14), and two from
animals that were not treated with artemether (RIc14 and RSb14); animals RFv14
and RMe14 were also treated with the AMD but samples from these animals did not
have sufficient parasite read depth for expression quantification (see Methods). As
before, I performed principal component analysis using the genes from each of the
life-stages. In this case, I use the first two principal components to plot each of the
samples in PC space.
In both the schizont- and the gametocyte-specific genes, the outlier point for
TP3 is from the primate that received artemether (Figure 29C,D). The two parasite
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Figure 28: Life-stage-specific gene set enrichment. For each pair-wise contrast
of the three experimental groups, the enrichment of life-stage for the three asexual IDC
forms (ring, trophozoite, and schizont) and the sexual development form (gametocyte)
is shown. For each plot, a vertical black line represents a gene specific to the given
life-stage. The bottom horizontal line which transitions from red to grey to blue
represents the t-statistic for the given contrast. Enrichment of genes on the left
side of the GSEA plot indicates coherent up-regulation in the group on the left of
the heading label. Enrichment of genes on the right side of the GSEA plot indicates
coherent up-regulation in the group on the right of the heading label (e.g. gametocyte
genes are up-regulated in TP3 compared to TP2; first column, last row).
populations from animals that did not receive the AMD have much higher relative
abundances of gametocytes, whereas in the parasite profile from the animal that did
receive the AMD is much closer to the TP2 profiles (D); the first PC explains 84% of
the variance in the gametocyte genes.
Interestingly, for the schizont-specific genes, the parasite profiles from TP3 are
all qualitatively similar to those of TP2 in the first principal component direction
(x-axis); this PC explains much of the variance and has been used to describe the
general trajectory of the genes in a group. However, the parasite profiles from the
two animals that did not receive the AMD have a qualitatively different location in
the second principal component (y-axis). This result suggests that there is a shift
in the underlying schizont gene expression program as the infection progresses, and
further, that this shift in schizont-specific genes is ablated by AMD treatment. I
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note that these differences are only suggestive of a trend and that I did not perform
statistical analysis on the differences between the three TP3 samples due to the lack
of replicates.
The PC loading plots of the ring- and trophozoite-specific gene sets show a general
lack tight co-regulation of expression of these genes (Figure 29E,F). In contrast, both
the schizont- and gametocyte-specific gene sets demonstrate a relatively high level of
expression coherence (Figure 29G,H).
5.4.7 Trajectory of selected multigene families
Plasmodium helical interspersed subtelomeric family (PHIST) proteins have recently
been shown to contain a erythrocyte cytoskeleton binding domain and consequently
may play an important role in the rigidity of the infected red blood cell (iRBC),
export of antigens, and formation of cytoadherence knobs, all of which play a role in
the virulence of the infection.[90]
Tryptophan-rich antigens (TRAs), another large multigene family present in many
Plasmodium species, are exported to the parasite cell membrane and may play a role
in erythrocyte binding and invasion, an important step in the parasite blood stage
progression.[95, 153, 21]
Both of the aforementioned protein families, PHIST and TRA, have a high ex-
pression at TP2, with lower expression level at later time points, TP3 and secondary
(Figure 30A,B). Furthermore, nearly all members of these two families are tightly
co-regulated (Figure 30C,D).
I also examined the expression trajectory of P. cynomolgi interspersed repeats
(CYIR) genes (the largest multigene family in this parasite species), but there was
no significant trend across experimental groups, nor was there expression coherence
in the principal component loadings, which shows that transcripts from these genes
are not co-regulated (not shown).
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Figure 29: Life-stage-specific gene expression. (A-D) Plots of the first two PCs
for the life-stage-specific gene sets. In all four plots, the two parasite profiles from TP3
(green inverted triangles) for the macaques that did not receive a sub-curative dose
of artemether are closer together than to the parasite profile from the macaque that
did receive the sub-curative artemether treatment. Samples from TP2, blue triangles;
samples from relapsing time points, gold circles. (E-H) Principal component loading
plots.
5.5 Discussion
In this study, I reported on parasite transcriptome-wide expression profiling across
multiple infection peaks, and determined that P. cynomolgi has a qualitatively differ-
ent gene expression profile between relapsing and primary parasitemias. Furthermore,
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Figure 30: Trajectory of PHIST proteins and tryptophan-rich antigens
(TRA) across the 100-day experiment. Composite measure of (A) PHIST pro-
tein and (B) TRA at the three clustered groups. Principal component loading of the
(C) PHIST and (D) TRA genes show tight coherence of expression with the first PC
explaining 76% and 80%, respectively.
the expression differences were life-stage coherent and indicated that the parasite pop-
ulations of the relapsing time points showed much lower relative abundance of the
sexual stage gametocytes.
5.5.1 Sexual stage abundance
A rather striking finding is that gametocyte-specific genes are lowly expressed in the
relapsing parasitemias compared to both the peak of parasitemia (TP2) and the later
stage of the first parasitemia peak (TP3) of the primary blood stage. This implies
that compared to the primary infection, relapsing parasitemias have a much lower
relative abundance of gametocytes that circulate in the blood. As suggested else-
where, transition from asexual to sexual forms may be due to either host or parasite
factors such as relative reticulocyte abundance or quorum sensing by microvesicle
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or exosome, respectively.[149, 150, 120] But the exact mechanisms controlling the
shift from asexual to sexual development are not completely understood.[3] The re-
sults from this study are inconclusive since reticulocyte data is not yet available, and
microvesicles were not interrogated. Gametocyte formation was qualitatively asso-
ciated with parasite abundance in the blood-stage, but a greater understanding of
gametocyte differentiation requires many more samples.
High gametocytemia in the primary infection and lower gametocyte production
in subsequent relapses may be adaptive and increase the fitness of the parasite in the
following way. When a naive host is infected with P. cynomolgi, there is a strong
host immune response. The parasites that most quickly shift from asexual to sexual
development and produce viable gametocytes to be taken up by a mosquito will leave
the most offspring.
Likewise, in an animal that survived the primary parasitemia, it may be advanta-
geous to the parasite to replicate asexually for a longer period of time. Regardless of
the evolutionary reason(s) for this behavior, the mechanism of control is likely to be
genetic and regulated in response to the host. As more data is gathered, analyzed,
and integrated, a deeper understanding of the mechanisms involved in gametocyte
commitment should begin to emerge.
5.5.2 Parasites from relapse spend less time in the schizont stage
In addition to the decreased number of gametocytes produces in the relapsing time
points, schizont-specific gene expression is also decreased. TP2 has the highest
schizont-specific expression, suggesting that parasites from TP2 –and to a lesser extent
TP3– spend more time in the schizont stage, which is when the parasite undergoes
asexual division to increase its numbers, compared to relapsing parasite populations.
The first peak of parasitemia is characterized by much higher parasite densities
which co-occurs with the longer duration spent in the schizont stage of the IDC. This
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association, while tentative based on the small sample size, should be further explored,
since controlling parasitemia levels and the resulting severe malarial symptoms is an
important goal in the treatment of this disease.
5.5.3 Previously observed effects of AMDs on parasite
Although there is only one sample for which I have parasite expression soon after
artemether administration, it appears that artemether reduced the abundance of ga-
metocytes in the blood stage, a finding consistent with previous reports.[48, 107, 50]
Interestingly, though, the relative level of gametocyte abundance after AMD treat-
ment is only comparable to that of TP2; in contrast, the relapsing parasite popula-
tions have a much lower gametocyte abundances. This finding re-affirms that there
are parasite regulatory networks that limit the production of gametocytes. Further
investigation into these networks and the genes important in gametocyte development
would facilitate drug development to target gametocyte activation pathways, thereby
limiting sexual-stage parasites and decreasing malaria transmission.
5.5.4 Caveats of this study
In this study, there were only 10 samples that contained a sufficient number of par-
asite reads to accurately quantify expression. This low number of samples decreased
statistical power to determine differential expression. In spite of this challenge, many
genes in coherent gene sets were identified as differentially regulated between the
experimental groups. Further, while some libraries had much fewer reads than oth-
ers, my down-sampling methodology demonstrated that the qualitative differences
between the experimental groups were robust to read sequencing depth.
In spite of the high depth of coverage of RNA-seq and the repeated measures
taken from the same animals across numerous time points, the causal direction can-
not be assigned between host and parasite transcriptome dynamics. That is, while I
have found qualitative differences in the parasite transcriptome between primary and
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relapse parasitemias, I cannot make the claim that the qualitatively different host
clinical parameters (anemia, thrombocytopenia, fever, lethargy, dehydration, etc.)
are being driven by the parasite transcriptome changes. Likewise, I cannot say that
the host immune response is causing the differences observed in the parasite tran-
scriptome. However, I have identified parasite transcriptional differences that are
associated with the severity of the malaria infection. These results should shape the
design of future experiments.
5.5.5 Future studies
Using this rich in vivo Plasmodium expression dataset, many additional analyses
could be performed. Firstly, I suggest that the shift in abundance of expressed alleles
should be tracked. That is, over the course of the experiment and in direct response
to the artificial selection imposed by the administration of anti-malarial drugs, advan-
tageous mutations may arise in the parasite. These mutations would then be selected
for if they offered a fitness advantage to the parasite. While this type of analysis has
never been performed previously and could have very important implications in our
understanding of the rate of evolution and selection occurring in the parasite genome
during an in vivo infection within a host, it may not be the best experiment to explore
this phenomenon.
In this P. cynomolgi infection, a completely curative dose of artemether was used
to eliminate the blood stage parasite. Subsequent relapsing parasitemias come from
the reactivation of dormant hypnozoites from the liver. These parasites are not af-
fected by the artemether, and so would not have experienced selection against the
oxidative stress induced primarily in the red blood cell. I would strongly advise,
however, that this type of analysis be performed in subsequent experiments, particu-
larly in the P. coatneyi infection, since in this experiment only subcurative doses of
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artemether are given. I would expect to see advantageous mutations arise which in-
crease the expression of proteins that can mitigate the increases in oxidative damage
to proteins and DNA.
Due to the nature of RNA-seq, the abundance of different isoforms for parasite
genes could also be explored. However, the number of Plasmodium genes shown to
have alternative isoforms is rather low (5% to 10%) compared to, say, Homo sapiens




In CHAPTER II, I outlined the analytical methods and integrative techniques which
were used in subsequent chapters. I showed also that the anti-malarial drug pyrimethamine
dysregulates numerous pathways in both the blood and bone marrow and that many
of the effects persist for at least 30 days after the administration of the drug. For
the treatment of malaria, which often requires only intermittent administration, these
host effects may not be of concern. However, in light of the possibility of re-purposing
this drug for the treatment of ALS, which would likely require a more regular usage,
further investigations into the safety of this drug need to be performed.
In CHAPTER III, I reported on the host transcriptional response to malaria
infection, and detail the qualitatively different host response between primary and
relapsing parasitemia peaks. The marked difference in magnitude of host transcrip-
tional changes between the primary and relapsing parasite peaks was unsurprising
given the vast difference in clinical parameters and outcomes between the two peak
types. However, there were qualitatively different pathways enriched in the relaps-
ing parasitemias. With the sparse sampling of this study, I cannot comment on the
day-to-day changes that may have occurred in either the primary or relapsing para-
sitemias. Follow-up studies with greater sampling rates are planned for later this year
and should yield greater insight into host immune response. Furthermore, transcrip-
tional profiling was performed on whole blood. In subsequent experiments, immune
cell subsets will be sorted and profiled separately, a study design change which should
give greater transcriptional resolution and ability to identify differential expression in
important cell types.
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In CHAPTER IV, I implemented a novel expression deconvolution method to
determine the life-stage composition of samples from a previously-reported P. fal-
ciparum IDC. Using this method, I was able to identify genes whose expression is
parasite stage-specific and used those gene sets in two subsequent chapters which
concerned parasite transcriptional profiling. In studies of gene expression profiling,
especially in Plasmodium where most genes have stage-specific expression, it will be
useful to employ expression deconvolution to estimate the abundance of cell types,
and then to subsequently use those estimates as both variables as well as covariate in
differential gene expression analysis.
In CHAPTER V, I identified qualitative alterations in the parasite transcriptome
between primary and relapsing infection peaks across a 100-day infection cycle. I
found that gametocytes were more abundant in parasite populations from untreated
animals compared to parasites from an animal treated with the anti-malarial drug
artemether. Due to a small sample size, it would be inappropriate to conclude that the
AMD caused the shift away from the production of the sexual stage of this parasite.
However, it does merit further investigation.
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